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Abstract  39 
Alpha-thalassemia X-linked intellectual disability (ATR-X) syndrome is caused 40 
by mutations in ATRX, which encodes a chromatin-remodeling protein. Genome-wide 41 
analyses in mouse and human cells indicate that ATRX tends to bind G-rich sequences 42 
with high potential to form G-quadruplexes. Here, we report that Atrx mutation induces 43 
aberrant upregulation of Xlr3b expression in mouse brain, an outcome associated with 44 
neuronal pathogenesis displayed by ATR-X model mice. We show that ATRX normally 45 
binds to G-quadruplexes in CpG islands of the imprinted Xlr3b gene, regulating its 46 
expression by recruiting DNA methyltransferases. Xlr3b binds dendritic mRNAs, and 47 
its overexpression inhibits dendritic transport of CaMKIIα mRNA, promoting synaptic 48 
dysfunction. Notably, treatment with 5-ALA, which is converted into 49 
G-quadruplex-binding metabolites, reduces RNA polymerase II recruitment and 50 
represses Xlr3b transcription in ATR-X model mice. 5-ALA treatment also rescues 51 
decreased synaptic plasticity and cognitive deficits seen in ATR-X model mice. Our 52 
findings suggest a potential therapeutic strategy to target G-quadruplexes and decrease 53 
cognitive impairment associated with ATR-X syndrome.  54 




ATR-X syndrome (OMIM Entry #301040) a severe intellectual disability, is 57 
caused by ATRX mutations 1-3. ATRX encodes the switch/sucrose nonfermentable 58 
(SWI/SNF)-like chromatin remodeling protein ATRX, which contains two signature 59 
motifs. One is a plant homeodomain (PHD) designated the ATRX-DNMT3-DNMT3L 60 
(ADD) domain, which binds histone H3 tails, specifically at H3K4me0K9me2/3 4-6. The 61 
other includes seven helicase subdomains that confer ATPase activity 7, 8.  62 
Genome-wide analysis combining chromatin immunoprecipitation with 63 
next-generation sequencing (ChIP-seq) in both primary human erythroid cells and 64 
mouse embryonic stem cells (ESCs) shows ATRX enrichment at G-rich variable number 65 
tandem repeats (VNTRs), some of which form non-B DNA structures, including 66 
G-quadruplexes 9. ATRX functions as a part of a histone chaperone complex that 67 
deposits the histone variant H3.3 onto pericentromeric heterochromatin and telomeres 68 
collaborating with death domain-associated protein (DAXX) in HeLa cells 10 and 69 
murine ESCs 11, 12. ATRX/H3.3 co-localization also occurs on the DNA-methylated 70 
allele of many imprinted genes and is associated with differentially methylated regions 71 
(DMRs) in mouse ESCs 13. Some imprinted genes show upregulated expression in 72 
forebrain of Atrx conditional knockout (cKO) mice 14, 15, suggesting that ATRX silences 73 
the active allele. Moreover, expression of the autism-related gene Nlgn4 significantly 74 
decreases in forebrain of Atrx cKO mice 16. Imprinting loss in neurons leads to various 75 
mental retardation syndromes, including Prader-Willi and Angelman syndromes 17. 76 
However, the relationship between abnormal expression and cognitive dysfunction in 77 
ATR-X syndrome remains unclear. 78 





ATRX regulates Xlr3b expression in mouse brain   82 
AtrxΔE2 mice, which are engineered to lack Atrx exon 2, show cognitive defects, 83 
among other phenotypes 18, and express a mutant protein that corresponds to a variant 84 
with an Arg37Stop (R37X) mutation in exon 2 seen in human ATR-X syndrome 19-21. 85 
Moreover, AtrxΔE2 mice show 80% reduction in ATRX protein levels 18, 19, similar to 86 
outcomes seen in 27 individuals with ATR-X syndrome 8. We employed DNA 87 
microarrays to assess transcriptional profiles at post-natal day (P) 90 in hippocampus of 88 
wild-type (WT) and AtrxΔE2 mice. To identify differentially-expressed genes, we used 89 
an algorithm combining false discovery rate (FDR) and fold-change in expression, and 90 
identified 31 genes (8 upregulated and 23 downregulated) in WT versus AtrxΔE2 91 
samples. Among them was Atrx itself, which was downregulated in AtrxΔE2 mice 92 
(Supplementary Table 1 for list of genes with an FDR < 0.05 and a log2 fold-change 93 
of > 0.5 or < −0.5). Among genes markedly upregulated in AtrxΔE2 mice were a member 94 
of the lymphocyte regulated (Xlr) gene family, Xlr3a and the imprinted gene Xlr3b 22-24 95 
(Fig. 1a, FDR < 0.05 and log2 fold-change of > 0.5). Xlr3a and Xlr3b genes show 94% 96 
protein similarity, and DNA microarrays are limited in their ability to distinguish related 97 
factors. Thus, we carried out reverse transcription-PCR (RT-PCR) analysis with a 98 
common forward primer and subtype-specific reverse primers (Supplementary Fig. 1a). 99 
Primer efficiency was confirmed by amplifying respective cDNAs (Supplementary Fig. 100 
1b), and distinct Xlr3a and Xlr3b amplicons were detected on gels (Supplementary Fig. 101 
1c, lanes 1 and 2). Then, using these primers, we detected Xlr3b, but not Xlr3a mRNA, 102 
in prefrontal cortex, hippocampus, hypothalamus and cerebellum of WT and AtrxΔE2 103 
mice (Supplementary Fig. 1c). Interestingly, quantitative RT-PCR (RT-qPCR) 104 
indicated Xlr3b transcript upregulation in some brain areas, including hippocampus, of 105 
AtrxΔE2 mice, but not in peripheral tissues (Fig. 1b). 106 
Next, in order to investigate changes in Xlr3 protein expression, we generated an 107 
Xlr3 antibody. To confirm its specificity, we performed Xlr3 knockout (KO)-validation 108 
using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 in 109 
cultured hippocampal neurons. To do so, we transduced cultured hippocampal neurons 110 
with lentivirus harboring U6gRNA-Cas9-2A-GFP plus guide Xlr3 sgRNA 111 
(Xlr3-Cas9-GFP) or control lentivirus expressing GFP. Microscopy analysis revealed 112 
loss of Xlr3 immunoreactivity in MAP2-positive neurons infected with Xlr3-Cas9-GFP 113 
but not control GFP virus (Supplementary Fig. 1d). We also confirmed Xlr3b KO 114 
efficacy by RT-qPCR in cultured hippocampal neurons (Supplementary Fig. 1e). 115 
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Western blot analysis with the Xlr3 antibody also showed significantly decreased 116 
protein expression in KO relative to WT cultured hippocampal neurons 117 
(Supplementary Fig. 1f), confirming antibody specificity. Next, we used the Xlr3 118 
antibody to examine Xlr3 protein expression in AtrxΔE2 mouse prefrontal cortex, 119 
hippocampus, hypothalamus and cerebellum tissues by western blot, and observed 120 
significant increases in Xlr3 protein levels in brain of AtrxΔE2 relative to WT mice (Fig. 121 
1c).    122 
CpG island (CGI) methylation by DNA methyltransferases (DMNTs) generally 123 
represses transcription 25, and cKO mice lacking Dnmt1 or both Dnmt1 and Dnmt3a in 124 
forebrain neurons show increased Xlr3b expression 26, 27. Although ATRX lacks a 125 
canonical DNA methyltransferase motif, human ATRX mutations are associated with 126 
altered DNA methylation patterns at various genomic loci 28. Moreover, Xlr3 gene CGIs 127 
display similar sequences, and a sequence potentially forming a G-quadruplex structure 128 
is specific to Xlr3b (Supplementary Fig. 2a). Thus, we asked whether ATRX recruits 129 
DNMTs to methylate Xlr3b CGIs. To do so, we employed bisulfite sequencing to 130 
compare DNA methylation levels in Xlr3b CGIs of whole brain samples from WT or 131 
AtrxΔE2 mice. Relative to WT mice, AtrxΔE2 mice showed significantly decreased DNA 132 
methylation at Xlr3b CGIs, while we observed no difference in DNA methylation levels 133 
in CGIs of other Xlr3 subfamily genes between genotypes (Fig. 1d, Supplementary 134 
Fig. 2b). Circular dichroism (CD) spectra of a synthetic oligodeoxynucleotide 135 
containing sequences potentially forming a G-quadruplex in Xlr3b CGIs (Xlr3b-ODN) 136 
showed a spectrum characteristic of parallel G-quadruplexes in 10 and 100 mM KCl, 137 
with maximum absorbance at 265 nm and minimum at 240 nm (Supplementary Fig. 138 
3a). This conformational change in physiological conditions (100 mM KCl) was 139 
reflected by decreased DNA mobility in gel shift assays performed using native 140 
polyacrylamide gel electrophoresis (PAGE) gels (Supplementary Fig. 3b). We then 141 
undertook dimethyl sulphate (DMS) footprinting of Xlr3b-ODN to assess formation of 142 
an intramolecular parallel G-quadruplex consisting of a core of three stacked G-quartets 143 
and three loops (Fig. 1e, Supplementary Fig. 3c). This analysis confirmed that Xlr3b 144 
CGI sequences can form parallel G-quadruplex structures. 145 
To assess how ATRX regulates Xlr3b, we performed luciferase reporter assays. 146 
To do so, we first cloned three different Xlr3b genomic sequences into a pGL3 147 
luciferase reporter vector. They included: a 2.0 kb fragment (designated pGL3-2K) 148 
upstream of the Xlr3b ATG initiation codon; a pGL3-2K deletion mutant lacking 149 
G-quadruplex-forming sequences (pGL3-2KΔG4); and a 1 kb Xlr3b upstream sequence 150 
(pGL3-1KΔCGI) that lacks CGIs. Mouse neuroblastoma Neuro-2a cells transfected 151 
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with pGL3-2K showed significantly reduced luciferase activity when co-transfected 152 
with ATRX; conversely, luciferase activity relative to controls increased in cells 153 
co-transfected with ATRX shRNA (Fig. 1f). However, cells transfected with either 154 
pGL3-2KΔG4 or pGL3-1KΔCGI showed activity comparable to cells co-transfected 155 
with ATRX or ATRX shRNA, suggesting that ATRX regulates Xlr3b through the 156 
G-quadruplex structure (Fig. 1f). We confirmed ATRX shRNA knockdown efficacy by 157 
immunoblotting for endogenous ATRX protein in Neuro-2a cells (Supplementary Fig 158 
4a). Moreover, Neuro-2a cells co-transfected with pGL3-2K plus DNMTs (DNMT1 or 159 
DNMT3A) showed significantly decreased reporter activity relative to respective 160 
controls (Fig. 1g). However, cells co-transfected with pGL3-2K plus DAXX or H3.3 161 
showed comparable reporter activity. Importantly, cells co-transfected with 162 
pGL3-2KΔG4 plus DNMTs showed no change in reporter activity relative to 163 
pGL3-2KΔG4 alone. Finally, we methylated pGL3-2K, pGL3-2KΔG4 and 164 
pGL3-1KΔCGI constructs using CpG DNA methyltransferase M.SssI and assessed the 165 
luciferase activity. We observed decreased luciferase activity in methylated pGL3-2K 166 
and pGL3-2KΔG4, not in methylated pGL3-1KΔCGI, supporting the idea that CGI 167 
methylation inhibits Xlr3b expression (Fig. 1g). 168 
To determine whether ATRX and interacting factors target Xlr3b CGIs in mouse 169 
hippocampus, we performed ChIP-qPCR with an ATRX antibody. We confirmed that 170 
hippocampal samples from AtrxΔE2 mice contained detectable levels of ATRX protein: 171 
those lysates showed an 80% reduction in ATRX protein levels relative to lysates from 172 
WT mice, and the ATRX antibody recognized both WT and mutant ATRX protein as 173 
described in 18, 19 (Supplementary Fig. 4b). Co-immunoprecipitation in hippocampal 174 
lysates revealed that ATRX interacts with DNMT1, DNMT3A, DAXX and H3.3 from 175 
both WT and AtrxΔE2 mice, and relatively low amounts of DNMT1, DNMT3A, H3.3 176 
and DAXX were detected in immunoprecipitated samples of AtrxΔE2 mice 177 
(Supplementary Fig. 4c). We detected substantial ATRX enrichment at Xlr3b CGIs 178 
containing G-quadruplexes based on ChIP analysis with primers targeting Xlr3b region 179 
R1 in chromatin isolated from WT mouse hippocampus, while ATRX interaction with 180 
chromatin at this site was greatly decreased in AtrxΔE2 hippocampus (Fig. 1h). Levels of 181 
DNMT1, DNMT3A, DAXX and H3.3 also significantly decreased in AtrxΔE2 relative to 182 
WT chromatin in the R1 region. Also, quantitative profiling of ATRX, DNMTs, DAXX 183 
and H3.3 across an unrelated R2 region revealed small peaks, demonstrating enrichment 184 
of these proteins at Xlr3b CGIs (Fig. 1h). These observations suggest overall that 185 
ATRX binds to parallel G-quadruplexes in Xlr3b CGIs along with DNMTs, DAXX and 186 




Neuronal RNA granules contain Xlr3b  189 
      We next undertook a proteomic screen to search for Xlr3 interaction partners by 190 
performing liquid chromatography-tandem mass spectrometry (LC-MS/MS) of proteins 191 
pulled down from lysates of P60 WT mouse brain with an Xlr3 antibody. LC-MS/MS 192 
analysis revealed an endogenous Xlr3 complex containing multiple components, 193 
including actin/myosin-related proteins, dynein motor complex (DYNLL, DYNLRB, 194 
DYNLT and DYNC1LI2) proteins, ribonucleoproteins (hnRNP A/B and hnRNP D), 195 
40S ribosomal proteins (RPS10 and RPS25), and others (Fig. 2a, Supplementary 196 
Table 2). We then confirmed association of purified GST-Xlr3b protein with hnRNP 197 
A/B, hnRNP D, DYNLL and DYNC1LI2 by in vitro pull-down assays in mouse 198 
hippocampal lysates (Fig. 2b). Purified Xlr3b protein did not bind F-actin, and its 199 
presence did not alter actin polymerization (Supplementary Fig. 5a, 5b). To confirm 200 
interactions in vivo, we performed immunoprecipitation of mouse hippocampal extracts 201 
with an Xlr3 antibody followed by immunoblotting with hnRNP A/B, hnRNP D, 202 
DYNLL, or DYNC1LI2 antibodies and observed co-precipitation of all with Xlr3 (Fig. 203 
2c).  204 
To determine Xlr3 cellular localization, we undertook immunofluorescence of 205 
mature MAP2-positive cultured neurons with an Xlr3 antibody. Xlr3 was localized to 206 
nuclei and perinuclear areas and seen in granules in MAP2-positive dendrites and in 207 
synaptic synaptophysin-positive puncta (Fig. 2d). Xlr3-positive structures of this type 208 
were also observed in MAP2-positive dendrites in mouse hippocampal CA1 analyzed at 209 
P60 (Fig. 2e). In dendrites, Xlr3-positive puncta co-localized with hnRNP A/B and 210 
cytotoxic granule-associated RNA binding protein 1 (TIA1), both found in RNA 211 
granules 29, and with SYTO14-visualized RNA. Xlr3-positive granules did not 212 
co-localize with DCP1a, a marker of RNA-processing bodies 29 (Fig. 2f).  213 
Xlr3b exhibits a predicted nuclear localization signal (NLS) at amino acid (AA) 214 
residues 2-11; residues 74-200 also constitute a conserved Cor1/Xlr/Xmr region (Cor1 215 
domain). To assess function of those sequences, we transfected Neuro-2a cells with 216 
FLAG-tagged Xlr3b or similarly-tagged deletion mutants shown in Figure 2g and 217 
analyzed their location by confocal microscopy (Fig. 2g). Based on FLAG expression, 218 
full length (FL)-Xlr3b significantly co-localized with TIA1 in nuclear regions compared 219 
to that of non-transfected cells. FL-Xlr3b also accumulated with hnRNP A/B in nuclei, 220 
but not with DCP1a (Fig. 2g, Supplementary Fig. 6a, 6b). Cells transfected with 221 
constructs lacking AA 2-11 (ΔNLS) or 74-123 (Δ74-123) showed partial loss of Xlr3b 222 
nuclear localization, but localization of the interacting proteins TIA1 and hnRNP A/B 223 
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was unchanged. These localization patterns were similar to those seen in 224 
FL-Xlr3b-transfected cells (Fig. 2g, Supplementary Fig. 6a, 6b). Deletion of AA 225 
124-200 (Δ124-200) caused loss of nuclear Xlr3b expression and localization of tagged 226 
protein in cytoplasmic ubiquitin-positive inclusion-like structures, in which DCP1a, 227 
TIA1 and hnRNP A/B were also colocalized. In addition, the Δ158-170 mutant was 228 
distributed similarly to the Δ124-200 mutant (Fig. 2g, Supplementary Fig. 6a, 6b and 229 
6c). Importantly, nuclear localization of TIA1 and hnRNP A/B in cells transfected with 230 
Δ124-200 or Δ158-170 constructs was very similar to patterns observed in 231 
non-transfected cells (Fig. 2g, Supplementary Fig. 6a).  232 
To confirm interactions of Xlr3b AA 158-170 with RNA binding proteins 233 
(RBPs), we used Xlr3b inhibitory peptide (XIP), a 29-AA peptide containing Xlr3b AA 234 
158-170 plus the cell-permeable antennapedia homeodomain (ANTP) peptide 235 
(Supplementary Fig. 7a). When FL-Xlr3b-transfected cells were treated with XIP 236 
(1μM for 4 h), TIA1 did not accumulate in the nucleus (Supplementary Fig. 7b). We 237 
confirmed that XIP, but not the ANTP control peptide, bound to RBPs, TIA1 and 238 
hnRNP A/B using pull-down assays of mouse hippocampal lysates with an ANTP 239 
antibody (Supplementary Fig. 7c). Immunoprecipitation confirmed that FLAG-tagged 240 
FL, Δ74-123, Δ124-200 and Δ158-170 mutants were immunoprecipitated with a FLAG 241 
antibody. Immunoblotting with TIA1 and hnRNP A/B antibodies detected 242 
immunoreactive TIA1 and hnRNP A/B bands in samples transfected with FL and 243 
Δ74-123, but not in Δ124-200 and Δ158-170. Remarkably, interactions with TIA1 and 244 
hnRNP A/B were not seen in FL-Xlr3b-transfected cells treated with 1μM XIP for 4 h 245 
before immunoprecipitation (Fig. 2h), suggesting that Xlr3b residues 158-170 are 246 
critical for RBP binding. Ubiquitination of Xlr3b ∆124-200 and ∆158-170 may prevent 247 
binding to RBPs, regardless of co-localization 30. Thus, to assess potential Δ124-200 248 
and Δ158-170 ubiquitination, we performed immunoprecipitation of lysates of cells 249 
transfected with FLAG-tagged FL, Δ74-123, Δ124-200 and Δ158-170 mutants with a 250 
FLAG antibody followed by immunoblotting with a ubiquitin antibody. We confirmed 251 
ubiquitination in immunoprecipitants of constructs ∆124-200 and ∆158-170, but 252 
ubiquitination was little seen in FL or Δ74-123 proteins (Supplementary Fig. 6d).  253 
Phylogenetic analysis identified the FAM9 gene family as human Xlr 254 
orthologues, and FAM9 proteins are predicted to have a Cor1 domain 32. BLAST 255 
searches indicated that Xlr3b residues 158-170 are highly conserved in Cor1 domains of 256 
FAM9 family proteins, including FAM9A and FAM9B (Supplementary Fig. 6e). We 257 
observed nuclear localization of FLAG-tagged FAM9A overexpressed in Neuro-2a cells, 258 
while a similar construct lacking residues analogous to Xlr3b 158-170 was found in 259 
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cytoplasmic inclusion body-like structures in a pattern similar to Xlr3b Δ158-170 260 
transfected cells (Supplementary Fig. 6e).  261 
  262 
Aberrant Xlr3b expression in neurons decreases synaptic plasticity by inhibiting 263 
transport of dendritic CaMKIIα mRNA 264 
In neurons, RNA granules are rapidly transported to dendrites, a process 265 
regulated by motor proteins 32. Some RBPs including hnRNP A/B recognize a specific 266 
cis-acting element termed the hnRNP A2 response element (A2RE) in mRNA 3' 267 
untranslated regions (3' UTRs); these include Ca2+/calmodulin-dependent protein kinase 268 
IIα (CaMKIIα), activity-regulated cytoskeleton-associated protein (Arc) and 269 
brain-derived neurotrophic factor (BDNF) 33. Because Xlr3b interacts with the dynein 270 
motor complex and RBPs, we hypothesized that Xlr3b regulates dendritic mRNA 271 
transport via a dynein-mediated transport mechanism.  272 
To test this hypothesis, we undertook RNA immunoprecipitation in mouse 273 
hippocampal lysates to determine whether an endogenous Xlr3 complex associates with 274 
dendritic mRNAs. After immunoprecipitation with an Xlr3 antibody, we isolated total 275 
RNA from precipitates and analyzed it by qPCR with primers specific to CaMKIIα, Arc 276 
and BDNF mRNA 3' UTRs. Immunoprecipitates contained all three mRNAs, and XIP 277 
treatment (1μM for 2h) of cell lysates significantly blocked these interactions (Fig. 3a).  278 
AtrxΔE2 mice show cognitive impairment and CaMKIIα dysfunction 18, 19. Thus 279 
we focused on dendritic CaMKIIα mRNA. To determine whether Xlr3b protein is 280 
co-transported into dendrites with CaMKIIα mRNA, we used dual-color time-lapse 281 
imaging with mCherry-Xlr3b and GFP-MS2-labeled CaMKIIα mRNA (GFP-CaMKIIα 282 
3′ UTR) 34. mCherry-Xlr3b co-localized with the GFP-CaMKIIα 3′ UTR, and both were 283 
co-transported to dendrites of cultured neurons (Fig. 3b). By contrast, co-localization of 284 
mCherry-Xlr3b mutants (∆124-200 and Δ158-170) with GFP-CaMKIIα 3′ UTR 285 
immunofluorescence was rarely seen (Supplementary Fig. 8a). To analyze dynamics 286 
of dendritic CaMKIIα mRNA transport, we investigated movement of the 287 
GFP-CaMKIIα 3′ UTR in proximal dendrites (20-100μm away from the cell body). 288 
Granules moved in anterograde (white arrowhead) and retrograde (yellow arrowhead) 289 
directions (Fig. 3c, top panel, left). Fig. 3c (top panel, right) shows a representative 290 
kymograph corresponding to 15-min of live imaging generated from a proximal 291 
dendrite that GFP-CaMKIIα 3' UTR (also see Supplementary Video 1). Imaging of 292 
GFP-CaMKIIα 3′ UTR movement revealed that approximately half of the observed 293 
CaMKIIα mRNA granules were immobile, and the few mobile granules showed 294 
bidirectional movement in cultured WT neurons. The number of bidirectionally-mobile 295 
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CaMKIIα mRNA granules significantly decreased in cultured neurons of transgenic 296 
mice overexpressing Xlr3b driven by the neuron-specific Thy1.2 promoter (Thy1-Xlr3b 297 
TG mice; Supplementary Fig. 9a-9d), relative to effects seen in WT neurons. 298 
Moreover, in cultured neurons of AtrxΔE2 mice, the number of bidirectionally-mobile 299 
CaMKIIα mRNA granules significantly decreased. Xlr3b-shRNA transfection or XIP 300 
treatment antagonized decreases in dendritic CaMKIIα mRNA transport seen in AtrxΔE2 301 
neurons, suggesting that Xlr3b acting through RBPs inhibits CaMKIIα mRNA transport 302 
(Fig. 3c, bottom). We confirmed efficacy of Xlr3b knockdown by immunoblotting of 303 
endogenous Xlr3 protein in cultured neurons (Supplementary Fig 9e). In addition, 304 
dynamics of CaMKIIα mRNA transport in distal dendrites (100-200μm from the cell 305 
body) was similar to that seen in proximal dendrites: bidirectionally-mobile CaMKIIα 306 
mRNA granules significantly decreased in Thy1-Xlr3b TG and AtrxΔE2 neurons relative 307 
to effects seen in WT neurons. Furthermore, Xlr3b-shRNA transfection or XIP 308 
treatment rescued decreases in dendritic CaMKIIα mRNA transport seen in AtrxΔE2 309 
neurons (Supplementary Fig. 8b, Supplementary Video 2).  310 
RNA granules localize beneath postsynaptic sites in dendrites, and CaMKIIα 311 
mRNA is located in dendrites and active postsynaptic regions 33. Indeed, the number of 312 
double-positive protein puncta containing the GFP-CaMKIIα 3′ UTR and the 313 
postsynaptic marker PSD95 significantly decreased in cultured neurons of Thy1-Xlr3b 314 
TG and AtrxΔE2 mice relative to the number seen in WT mice, and cultured neurons 315 
from AtrxΔE2 mice transfected with Xlr3b shRNA or treated with XIP showed a 316 
significant increase in the number of double-positive puncta (Fig. 3d). Next, we 317 
performed western blot analysis for CaMKIIα protein in synaptosomal membrane 318 
fractions, containing PSD95 isolated from cultured hippocampal neurons 319 
(Supplementary Fig. 9f). CaMKIIα protein was decreased in the synaptosomal 320 
membrane fractions from cultured neurons of Thy1-Xlr3b TG and AtrxΔE2 mice relative 321 
to that seen in WT mice. XIP treatment in AtrxΔE2 neurons significantly increased in the 322 
synaptosomal CaMKIIα protein levels without changes in both CaMKIIα and PSD95 323 
levels in total cell lysate fractions between groups (Supplementary Fig. 9f). 324 
Dendritic CaMKIIα mRNA translation is regulated by synaptic activity, and 325 
postsynaptic CaMKIIα protein regulates hippocampal long-term potentiation (LTP), 326 
which is critical for learning and memory 35-38. To assess a potential effect on LTP, we 327 
undertook electrophysiological analysis of brain slices from hippocampal CA1. 328 
Consistent with our previous study 19, we observed markedly reduced high frequency 329 
stimulation (HFS)-induced LTP in AtrxΔE2 mice, which was significantly rescued by a 2 330 
h bath application of XIP to AtrxΔE2 mouse samples, but not following application of an 331 
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ANTP control peptide, suggesting that impaired LTP seen in AtrxΔE2 mice is in part 332 
Xlr3b-dependent (Fig. 3e). Notably, Thy1-Xlr3b TG mice also showed impaired 333 
hippocampal LTP (Supplementary Fig. 9g). We observed no significant difference in 334 
basic electrophysiological properties, among them input-output relations and 335 
paired-pulse ratio, between groups (Supplementary Fig. 9h). LTP induction, which 336 
strengthens synapses, results in CaMKII phosphorylation throughout the dendritic area, 337 
suggesting widespread CaMKII activation including in spines 39, 40. In WT mice, levels 338 
of CaMKIIα phosphorylation significantly increased following hippocampal LTP 339 
induction. Consistent with LTP impairment, CaMKIIα phosphorylation did not increase 340 
following LTP induction in hippocampus of AtrxΔE2 and Thy1-Xlr3b TG mice. Notably, 341 
bath application of XIP, but not ANTP, significantly restored LTP-induced CaMKIIα 342 
phosphorylation in the AtrxΔE2 hippocampus (Supplementary Fig. 9i).  343 
To assess whether Xlr3b overexpression affects cognitive function, we employed 344 
a novel object recognition task. In training trials, we observed no differences in the 345 
discrimination index using the same object between WT and Thy1-Xlr3b TG mice (data 346 
not shown). After a 24 h retention interval between trial and test sessions, Thy1-Xlr3b 347 
TG mice showed a significantly lower discrimination index for a novel object than did 348 
WT mice (Supplementary Fig. 9j). To assess contextual memory, we undertook a 349 
fear-conditioned passive avoidance task and observed no significant differences in 350 
latency to enter a dark room in the absence of foot shock between WT and Thy1-Xlr3b 351 
TG mice (data not shown). However, latency to enter the dark compartment was 352 
markedly decreased 1-week after foot shock in Thy1-Xlr3b relative to WT mice 353 
(Supplementary Fig. 9k). We then used a Y-maze to test spatial working memory and 354 
observed that Thy1-Xlr3b mice showed impairment based on the percentage of 355 
alternation behaviors relative to WT mice without a change in the total number of arm 356 
entries (Supplementary Fig. 9l). 357 
 358 
5-ALA treatment reduces RNA polymerase II recruitment and represses Xlr3b 359 
transcription by modifying G-quadruplex structure.  360 
G-quadruplex-binding small molecules such as porphyrin function as 361 
transcriptional repressors 41. Thus, we asked whether Xlr3b repression via porphyrin 362 
binding its G-quadruplex structure would antagonize synaptic dysfunction and cognitive 363 
deficits seen in AtrxΔE2 mice. To do so, we first assessed intracellular generation of 364 
porphyrins following administration of 5-aminolevulinic acid (5-ALA), which can be 365 
metabolized to porphyrins, protoporphyrin IX (PpIX) and hemin 42 (Fig. 4a). We 366 
confirmed PpIX and hemin binding to Xlr3b-ODN G-quadruplexes using UV melting 367 
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analysis. The ΔTm for PpIX and hemin was 2.0 and 2.3°C, respectively, indicating that 368 
PpIX and hemin both moderately bind Xlr3b G-quadruplexes structure. The ΔTm for 369 
TMPyP4, a well-known G-quadruplex binding ligand, was higher than 4°C 370 
(Supplementary Fig. 10a). To determine whether 5-ALA treatment alters Xlr3b gene 371 
expression, we transfected Neuro-2a cells with the pGL3-2K reporter, treated cells with 372 
varying concentrations of 5-ALA or TMPyP4, and assessed effects of Xlr3b expression 373 
based on luciferase assays. As expected, treatment with 5-ALA or TMPyP4 reduced 374 
luciferase activity dose-dependently but had no effect on cells transfected with 375 
pGL3-2KΔG4 (Fig. 4b, Supplementary Fig. 10b). Decreased luciferase activity in 376 
5-ALA treated cells was efficiently rescued by co-treatment with the 5-ALA 377 
dehydratase inhibitor succinylacetone (Fig. 4c). Next, we asked whether treatment with 378 
G-quadruplex ligands would inhibit aberrant Xlr3b gene expression seen in AtrxΔE2 379 
mouse brain. To do so, we administered 5-ALA (p.o. daily from P30 to P90) or 380 
TMPyP4 (i.p. twice weekly from P30 to P90). Either treatment significantly blocked 381 
increases in hippocampal Xlr3b mRNA and Xlr3 protein seen in vehicle-treated AtrxΔE2 382 
mice (Fig. 4d and 4e, Supplementary Fig. 10c and 10d).  383 
To investigate mechanisms underlying these effects, we undertook bisulfite 384 
sequencing to compare DNA methylation levels. Xlr3b CGIs in hippocampus and 385 
prefrontal cortex of AtrxΔE2 mice showed significantly decreased DNA methylation 386 
relative to WT mice, an effect unchanged by 5-ALA treatment (Fig. 4f, Supplementary 387 
Fig. 10e). Next, we performed ChIP-qPCR of ATRX and RNA polymerase II (Pol II) 388 
within the Xlr3b gene, as G-quadruplex structures hinder Pol II passage 43, 44. The 389 
prediction of quadruplex structures within the Xlr3b gene was supported by the 390 
G-quadruplex analysis tool QGRS Mapper 45 (Fig. 4g, top). In WT mouse hippocampus, 391 
ATRX and Pol II accumulated at Xlr3b CGIs containing G-quadruplexes, based on 392 
analysis using primers targeting amplicon 1, but little signal was seen at amplicons 2, 3 393 
and 4 (Fig. 4g, bottom). However, in AtrxΔE2 mouse, we detected an elevated Pol II 394 
signals across all amplicons in the Xlr3b gene body as well as CGIs, indicating 395 
enhanced Xlr3b transcription. Furthermore, elevated Pol II signals were significantly 396 
attenuated following 5-ALA treatment (Fig. 4g, bottom). These results suggest that the 397 
porphyrin metabolites PpIX and hemin, which are derived from 5-ALA, bind Xlr3b 398 
G-quadruplex structures, partially reducing Pol II recruitment. 399 
 400 
Treatment with G-quadruplex ligands counteracts cognitive deficits seen in 401 
AtrxΔE2 mice. 402 
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Next, we asked whether 5-ALA treatment rescued decreases in dendritic 403 
CaMKIIα mRNA transport seen in AtrxΔE2 neurons. Imaging of GFP-CaMKIIα 3′ UTR 404 
movement revealed that the decreased number of bidirectionally-mobile CaMKIIα 405 
mRNA granules was significantly rescued in 5-ALA treated AtrxΔE2 neurons (7 days, 406 
1μM) at proximal and distal dendrites (Fig. 5a, Supplementary Fig. 11a). The 407 
decreased number of double-positive protein puncta containing GFP-CaMKIIα 3′ UTR 408 
and PSD95 in AtrxΔE2 neurons was also significantly rescued (Fig. 5b). Moreover, 409 
reduced HFS-induced LTP in hippocampus of vehicle-treated AtrxΔE2 mice was 410 
significantly restored in 5-ALA-treated AtrxΔE2 mice (p.o. daily from P30 to P90) 411 
without a change in basic electrophysiological properties (Fig. 5c, Supplementary Fig. 412 
11b). Finally, 5-ALA treatment significantly blocked decreased CaMKIIα protein level 413 
at synaptosomal membrane fractions in cultured hippocampal neurons from AtrxΔE2 414 
mice, and restored LTP-induced CaMKIIα phosphorylation in hippocampus of AtrxΔE2 415 
mice (Supplementary Fig. 11c).  416 
We next administered 5-ALA (p.o. daily from P30 to P90) or TMPyP4 (i.p. 417 
twice weekly from P30 to P90) to AtrxΔE2 mice and subsequently assessed 418 
memory-related behaviors. We observed no differences in a novel object recognition 419 
task in the discrimination index using the same object in all groups in training trials 420 
(data not shown). After a 24h retention interval between trial and test sessions, AtrxΔE2 421 
mice showed a significantly lower discrimination index for a novel object than did WT 422 
mice. The discrimination index for the novel object in AtrxΔE2 mice treated with 5-ALA 423 
or TMPyP4 was significantly higher than that seen in vehicle-treated groups (Fig. 5d, 424 
Supplementary Fig. 11d). In a fear-conditioned passive avoidance task, we observed 425 
no significant differences in latency to enter a dark room in the absence of foot shock in 426 
all groups (data not shown). However, latency to enter a dark compartment was 427 
markedly decreased 1-week after foot shock in AtrxΔE2 relative to WT mice. 5-ALA or 428 
TMPyP4 administration also significantly rescued reduced latency time (Fig. 5e, 429 
Supplementary Fig. 11e). In a Y-maze test, AtrxΔE2 mice showed impairment based on 430 
the percentage of alternation behaviors relative to WT mice without a change in the total 431 
number of arm entries. 5-ALA or TMPyP4 administration significantly increased the 432 
percentage of spontaneous alternation behaviors in AtrxΔE2 mice (Fig. 5f, 433 
Supplementary Fig. 11f). Many patients with ATR-X syndrome exhibit abnormal 434 
social behaviors, especially shyness and social withdrawal 46. Interestingly, in 435 
interactions with WT mice, AtrxΔE2 mice showed enhanced passivity, greater escape 436 
duration and decreased active social behaviors, such as following and sniffing. These 437 
changes were dramatically ameliorated in AtrxΔE2 mice (Supplementary Fig. 11g). 438 
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Acute administration of a single 5-ALA dose (10mg/kg, p.o.) did not ameliorate 439 
impaired learning and memory-related behaviors in AtrxΔE2 mice (data not shown).  440 
To confirm that TMPyP4 was present in brain, we measured TMPyP4 441 
fluorescence levels, as described in 47. Chronic intraperitoneal injection of TMPyP4 (i.p. 442 
twice weekly from P30 to P90) in mice increased fluorescence levels in some tissues, 443 
including brain, suggesting that treatment allows intracerebral transferability and 444 
enables TMPyP4 accumulation in brain tissue (Supplementary Fig. 11h). However, we 445 
stopped chronic TMPyP4 administration on day 60 due to toxicity, as evidenced by 446 
reduced body weight (Supplementary Fig. 11i). Unlike the case with TMPyP4, 5-ALA 447 
pharmacokinetics and biodistribution, including in brain, has been reported in humans 48 448 
and rodents 49. We confirmed that 5-ALA crosses the blood brain barrier after oral 449 
administration. In mouse brain, 5-ALA (3mg/kg, p.o.) levels peaked at 30min and then 450 
decreased to basal levels by 24h after administration (Supplementary Fig. 11j). 451 
To investigate expression of other genes underlying these effects, we performed 452 
DNA microarray analysis of RNA extracted from hippocampus of P90 WT, AtrxΔE2, or 453 
5-ALA treated AtrxΔE2 mice, and focused on 31 genes differentially expressed (8 454 
upregulated and 23 downregulated) in WT versus AtrxΔE2 samples using a threshold of 455 
FDR <0.05 and log2 fold-change of > 0.5 or < -0.5 (Supplementary Table 1). Rescued 456 
or not rescued genes were assessed using the difference between the average value in 457 
log2 global normalization. 5-ALA treatment of AtrxΔE2 mice significantly blocked 458 
differential expression of 71.0% of genes including Xlr3b (Fig. 5g, Supplementary 459 
Table 3). Following analysis of mice treated with TMPyP4, we selected 138 genes 460 
differentially expressed (38 upregulated and 100 downregulated) in WT versus AtrxΔE2 461 
hippocampal samples using a threshold of log2 fold-change of > 1.0 or < -1.0. TMPyP4 462 
treatment of AtrxΔE2 mice blocked differential expression of 92.8% of genes including 463 
Xlr3b, leaving only 10 of 138 genes remained differentially expressed (Supplementary 464 





Here, we make several critical observations relevant to activities of ATRX 468 
(Supplementary Fig. 12). (1) ATRX binds to parallel G-quadruplexes in Xlr3b CGIs 469 
together with DNMTs, DAXX and H3.3, where it regulates Xlr3b gene expression. (2) 470 
Cognitive deficits seen in AtrxΔE2 mice are accompanied by Xlr3b upregulation, which 471 
inhibits CaMKIIα mRNA transport in neuronal dendrites. (3) Abnormal neuronal 472 
phenotypes exhibited by AtrxΔE2 mice are rescued by treatment with 5-ALA, a 473 
G-quadruplex ligand that inhibits Xlr3b expression.  474 
Among genes altered in AtrxΔE2 mouse brain, the imprinted gene Xlr3b is 475 
significantly overexpressed. ATRX is enriched with DNMTs at G-quadruplexes in Xlr3b 476 
CGIs. We observed that reduced ATRX levels at a given site were accompanied by 477 
reduced DNMT levels and substantial DNA demethylation, suggesting that ATRX 478 
regulates DNA methylation by DNMT recruitment to G-quadruplexes. Notably, 479 
forebrain-specific cKO of either DNMT1 or both DNMT1 and DNMT3A reportedly 480 
promotes increased Xlr3b expression in excitatory neurons 26, 27. Moreover, recent 481 
genome-wide analysis revealed preferential ATRX localization at the DNA-methylated 482 
allele of many imprinted DMRs in mouse ESCs and that ATRX-bound CGI sequences 483 
were methylated to a greater extent than that seen in other parts of the genome 13. 484 
ATRX deficiency also correlates with reduced H3.3 incorporation and with Pol II 485 
stalling at G-rich intragenic sites, indicating that ATRX influences Pol II-mediated 486 
transcription 16. Accordingly, we detected Pol II accumulation at Xlr3b CGIs harboring 487 
G-quadruplexes in WT hippocampus. We also found that cells in the AtrxΔE2 488 
hippocampus showed enriched Pol II signals across the Xlr3b gene relative to cells from 489 
WT brain, and elevated Pol II signals in AtrxΔE2 hippocampus were significantly 490 
attenuated following 5-ALA treatment without changing DNA methylation levels. These 491 
results suggest that the porphyrin metabolites PpIX and hemin, which are derived from 492 
5-ALA, bind G-quadruplex structures, partially inhibiting Pol II recruitment, a 493 
mechanism supported by biophysical analysis of G-quadruplexes in the HIF1A, KRAS, 494 
CMYB and CMYC genes 41. The G-quadruplex structure formed behind advancing Pol II 495 
may be recognized by other factors, including positive transcription elongation factor b 496 
50. In this context, further studies are required to define dynamic transcriptional 497 
structures interacting with the region bearing G-quadruplex motifs and how they 498 
regulate ATRX-mediated DNA methylation and Pol II recruitment. 499 
We also report a novel role for Xlr3b as a component of RNA granules 500 
containing RBPs, which inhibit CaMKIIα mRNA transport into neuronal dendrites. 501 
Xlr3b interacted with the dendritic mRNAs CaMKIIα, Arc and BDNF via a 13 AA Cor1 502 
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domain, which binds RBPs. This sequence is required for CaMKIIα mRNA transport, 503 
suggesting that RBP binding is also necessary for transport. Interestingly, that Xlr3b 504 
sequence is highly conserved in human FAM9 proteins, which also exhibit a Cor1 505 
domain. Thus, binding ability may be common to proteins containing Cor1/Xlr/Xmr 506 
motifs. In addition, our fluorescence imaging and electrophysiological analysis supports 507 
the idea that Xlr3b negatively regulates synaptic plasticity by inhibiting dendritic 508 
CaMKIIα mRNA transport in AtrxΔE2 mice. Mice engineered to lack the CaMKIIα 509 
mRNA 3′ UTR showed reduced levels of CaMKIIα transcripts at postsynaptic densities, 510 
reduced LTP, and impaired spatial memory 38. Dendritic transport and local translation 511 
of BDNF and Arc mRNA in synapses also enhances neuronal activity 33, strongly 512 
suggesting that Xlr3b-mediated dendritic mRNA transport is related to learning and 513 
memory functions. 39XmO mice, a murine model of the female developmental disorder 514 
Turner syndrome, show aberrantly high Xlr3b expression in brain, an outcome 515 
associated with difficulties in performing a reversal learning test, relative to 40XX and 516 
39XpO mice 24, suggesting that Xlr3b governs mouse behaviors. However, mechanisms 517 
underlying these activities remain unknown. We also demonstrated that Thy1-Xlr3b TG 518 
mice show impaired LTP and memory deficits, indicating that aberrant neuronal Xlr3b 519 
expression partially affects dendritic mRNA transport and learning behaviors in AtrxΔE2 520 
mice.  521 
We also show that administration of the G-quadruplex ligands 5-ALA or 522 
TMPyP4 significantly rescues neuronal phenotypes seen in AtrxΔE2 mice by inhibiting 523 
Xlr3b transcription. However, recovery of cognitive deficits in AtrxΔE2 mice following 524 
5-ALA administration may be due in part to the binding of ligand to G-quadruplexes of 525 
other ATRX targets, although this activity remains unknown. G-quadruplex motifs 526 
broadly influence transcription and translation 41. In addition, ATRX can either repress 527 
or activate gene expression through G-quadruplexes 9, 51, 52. Although potential 528 
off-target effects remain to be investigated, our findings suggest a novel therapeutic 529 
strategy aimed at blocking Xlr3b expression through small molecule binding to 530 
G-quadruplex DNA in patients with ATR-X syndrome. Among candidate ligands, 531 
5-ALA has been applied clinically with minimal risk and approved for use following 532 
intracranial tumor resection in Europe, Canada, and Japan 53, where it has been used as a 533 
photosensitizer in photodynamic diagnostics applied in neurosurgery 54. 5-ALA is also 534 
safe when administered chronically up to 200 mg per day in humans 55. Thus, its 535 
approval time would be short and the cost of clinical trials would be reduced, as 536 
pre-existing absorption, distribution, metabolism, excretion (ADME) and toxicity data 537 
is available. Finally, the risk of failure is reduced as data relevant to 5-ALA safety and 538 
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pharmacology is available.  539 
In summary, our study indicates that G-quadruplex ligands regulate gene 540 
expression through a transcriptional mechanism involving Xlr3b and could be used to 541 
treat symptoms associated with ATR-X syndrome.  542 
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Figure legends (for main text only) 789 
 790 
Figure 1. ATRX regulates Xlr3b gene expression. a, Heat map summarizing 791 
expression data, and a list of genes exhibiting differential expression between WT and 792 
AtrxΔE2 mouse hippocampus at post-natal day (P) 90 (an FDR < 0.05 and a log2 793 
fold-change of > 0.5). See also Supplementary Table 1 (a list of genes with an FDR < 794 
0.05 and a log2 fold-change of > 0.5 or < −0.5). n = 7 mice each. b, Quantitative 795 
real-time RT-PCR showing Xlr3b mRNA expression in mouse lysates. **P < 0.01 by 796 
two-way ANOVA with Bonferroni's post hoc test; n = 8-12 mice at P90. PC, (n=8 each); 797 
HP, (n=10 each); HT, (WT, n=10; AtrxΔE2 n=8); CE, (WT, n=9; AtrxΔE2, n=10); lung, 798 
liver, heart, and kidney, (n=12 each). PC, medial prefrontal cortex; HP, hippocampus; 799 
HT, hypothalamus; CE, cerebellum. c, (top) Representative immunoblot of P90 mouse 800 
brain lysates probed with indicated antibodies. (bottom) Densitometric analysis of Xlr3 801 
normalized to β-tubulin (arbitrary units, A.U.). **P < 0.01, *P < 0.05 by two-way 802 
ANOVA with Bonferroni's post hoc test; n = 4 mice each. d, Percentage of 803 
5-methylcytosine (5-mC) as determined by bisulfite sequencing analysis in whole brain 804 
from male P90 WT or AtrxΔE2 mice. **P < 0.01 by two-sided unpaired t test. n = 12 805 
clones each. (n = 3 mice each, 4 clones were sequenced per mouse). See also 806 
Supplementary Fig. 2. e, Xlr3b-ODN showing intramolecular parallel G-quadruplexes, 807 
which formed three separate G-quartets stacked 5′ to 3′ with three loops. f and g, 808 
Luciferase activity of Neuro-2a cells co-transfected with plasmids identified in left 809 
margin plus other indicated plasmids. Luciferase activity is presented relative to its 810 
activity in mock cells. **P < 0.01 by one-way ANOVA with Bonferroni's post hoc test; 811 
n = 6 biologically independent samples. h, (top) Schematic diagram of Xlr3b: 812 
G-quadruplex-forming sequence (yellow), CGI (gray) and R1 and R2 regions. (bottom) 813 
Analysis of R1 and R2 regions in chromatin from hippocampus of AtrxΔE2 and WT mice 814 
by chromatin immunoprecipitation with indicated antibodies. Results are expressed as 815 
percent input. **P < 0.01, *P < 0.05 by two-sided unpaired t test. n = 6 mice at P90. 816 
Full-size scans of western blots shown in Supplementary Fig. 13. 817 
 818 
Figure 2. Xlr3b is found in neuronal RNA granules. a, Pull-down assay and 819 
LC-MS/MS analysis of Xlr3-interacting proteins from P60 mouse brain lysates using an 820 
Xlr3 antibody. (left) Silver-stained SDS-PAGE gel of protein A sepharose column 821 
eluates with rabbit IgG (lane 1) or an Xlr3 antibody (lane 2) in mouse brain lysates. 822 
(right) Distribution of identified proteins in a shotgun proteomics experiment. b, 823 
Immunoblot analysis of GST affinity-column eluates using P60 mouse hippocampal 824 
26 
 
lysates. Aliquots of extracts (1% input) and eluates were subjected to SDS-PAGE and 825 
immunoblotted with indicated antibodies. The experiments were repeated three times 826 
with similar results. c, Immunoprecipitation (IP) assay with an Xlr3 antibody from P60 827 
mouse hippocampal lysates. Precipitated proteins and inputs were immunoblotted with 828 
indicated antibodies. Aliquots of extracts (1% input) and eluates were subjected to 829 
SDS-PAGE. The experiments were repeated three times with similar results. d, 830 
Confocal images showing co-localization of Xlr3 (green) with synaptophysin (red) and 831 
MAP2 (blue) in primary mouse cultured neurons at day 21 in vitro. Arrowheads indicate 832 
synaptophysin-positive puncta. Scale bars: (top) 10μm, (bottom) 5μm. e, Confocal 833 
images show co-localization of Xlr3 (green) with MAP2 (magenta) in mouse 834 
hippocampal CA1. Images at bottom are high-magnification. Scale bars, 10μm. f, 835 
Confocal images showing co-localization of Xlr3 (magenta) with hnRNP A/B, TIA1, 836 
SYTO14 and DCP1a (green) in primary mouse cultured neurons at day 21 in vitro. 837 
Images at left are enlarged from corresponding boxed areas. Scale bars, 10μm. g, (top) 838 
Schematic representation of Xlr3b construct. Xlr3b contains a predicted typical nuclear 839 
localization signal (NLS) from residues 2-11 and a Cor1/Xlr/Xmr conserved region 840 
(Cor1) domain at residues 74-200. (bottom), Confocal images show co-localization of 841 
FLAG-tagged Xlr3b constructs (green) with TIA1 (red) in Neuro-2a cells. Nuclear DNA 842 
is labeled with DAPI (blue). Scale bars, 10μm. h, Neuro-2a cells were transfected with 843 
FLAG-tagged Xlr3b constructs, cell lysates were immunoprecipitated (IP) with 844 
anti-FLAG antibody, and western blots (WB) were probed with indicated antibodies. To 845 
validate an inhibitory effect of XIP, cells were treated 4 h with XIP peptides (1μM). In 846 
d-h, the experiments were repeated three times with similar results. Full-size scans of 847 
western blots shown in Supplementary Fig. 13. 848 
 849 
 850 
Figure 3. Aberrant Xlr3b expression perturbs synaptic plasticity by inhibiting 851 
dendritic CaMKIIα mRNA transport. a, Xlr3 interacts with CaMKIIα, Arc and 852 
BDNF mRNAs in an RNA immunoprecipitation assay. Total mRNA was precipitated 853 
from P90 mouse hippocampal lysates with an Xlr3 antibody. cDNA was analyzed with 854 
primers amplifying CaMKIIα, Arc and BDNF mRNAs. **P < 0.01 by one-way ANOVA 855 
with Bonferroni's post hoc test; n = 5 mice each. b, Time-lapse images of 856 
mCherry-Xlr3b (red) and GFP-CaMKIIα 3′ UTR (green) co-transported in a dendrite of 857 
cultured neuron at day 21 in vitro. Granules moved in both anterograde (white 858 
arrowhead) and retrograde (yellow arrowhead) directions. Scale bars, 3μm. The 859 
experiments were repeated three times with similar results. c, (top, right) Representative 860 
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kymograph of movement of GFP-CaMKIIα 3′ UTR in a proximal dendrite. Scale bars, 861 
5μm (x-axis) and 5min (y-axis). (top, left) Granules moved in anterograde (white 862 
arrowhead) and retrograde (yellow arrowhead) directions. Scale bars, 2μm. See also 863 
Supplementary Video 1. (bottom) Relative frequency of movement of GFP-CaMKIIα 864 
3′ UTR granules. **P < 0.01 by two-way ANOVA with Bonferroni's post hoc test; n = 5 865 
neurons each, a proximal dendrite (20-100μm away from the cell body) per neuron to 866 
measure relative frequencies. Cells were treated with XIP (1μM) 4 h before imaging. 867 
Imm., immobile; Bidirect., bidirectional movement; Antero., anterograde movement; 868 
and Retro., retrograde movement. d, The number of GFP-CaMKIIα 3′ UTR (green) and 869 
PSD95 (magenta) double-positive puncta. **P < 0.01 by one-way ANOVA with 870 
Bonferroni's post hoc test; n = 20 neurons each, a proximal dendrite (20-100μm away 871 
from the cell body) per neuron. Whiskers represent minima and maxima. e, (left) 872 
Representative field excitatory post-synaptic potentials (fEPSPs) were recorded from 873 
the hippocampal CA1 region of mice. (middle) Changes in fEPSP slope following high 874 
frequency stimulation (HFS) recorded in hippocampal CA1. (right) Changes in fEPSP 875 
slope following HFS at 1 or 60 min based on analysis shown at left. **P < 0.01, *P < 876 
0.05 by two-way ANOVA with Bonferroni's post hoc test; WT, AtrxΔE2, AtrxΔE2 + XIP, n 877 
= 8 mice; AtrxΔE2 + ANTP, n=6 mice. 878 
 879 
Figure 4. 5-ALA represses Xlr3b transcription with RNA polymerase II 880 
recruitment by modifying G-quadruplex structure. a, 5-ALA metabolism to 881 
indicated porphyrins. Succinylacetone inhibits 5-ALA dehydratase (ALAD). PBG, 882 
porphobilinogen; PpIX, protoporphyrin IX; FECH, ferrochelatase. b and c, Luciferase 883 
activity in Neuro-2a cells transfected with pGL3-2K or pGL3-2KΔG4 and treated with 884 
5-ALA (0.1, 0.3, 1, 3 or 10μM) (b), or co-administered 10μM 5-ALA and 885 
succinylacetone at 1, 10, 100 or 1000μM (c) for 48h. Luciferase activity is shown 886 
relative to that in vehicle-treated cells. **P < 0.01 by one-way ANOVA with 887 
Bonferroni's post hoc test; n = 3 biologically independent samples. d, Quantitative 888 
real-time RT-PCR showing Xlr3b mRNA expression in P90 mouse hippocampal lysates. 889 
**P < 0.01 vs. vehicle-treated WT mice, ##P < 0.01 vs. vehicle-treated AtrxΔE2 mice by 890 
one-way ANOVA with Bonferroni's post hoc test; n = 6 mice each. e, (top) 891 
Representative immunoblot of P90 mouse brain lysates probed with indicated 892 
antibodies. (bottom) Densitometric analysis of Xlr3 normalized to β-tubulin (arbitrary 893 
units, A.U.). **P < 0.01 vs. vehicle-treated WT mice, ##P < 0.01 vs. vehicle-treated 894 
AtrxΔE2 mice by one-way ANOVA with Bonferroni's post hoc test; n = 4 mice each. f, 895 
Percentage of 5-methylcytosine (5-mC) as determined by bisulfite sequencing analysis 896 
28 
 
in medial prefrontal cortex (PC) and hippocampus (HP) from male P90 WT or AtrxΔE2 897 
mice. **P < 0.01 by two-way ANOVA with Bonferroni's post hoc test; n = 9 clones. 898 
(n = 3 mice. 3 clones were sequenced per mouse.) See also Supplementary Fig. 10e. g, 899 
(top) The G-quadruplex prediction tool GQRS mapper was used to identify potential 900 
G-quadruplex forming sequences in the entire Xlr3b genomic DNA sequence, which is 901 
shown with exons highlighted in black and introns highlighted in gray. GQRS mapper 902 
provides a G-score (plotted in blue) which indicates the likelihood of G-quadruplex 903 
formation. Image is adapted from QGRS mapper 904 
(http://bioinformatics.ramapo.edu/QGRS/index.php). (bottom) Analysis of indicated 905 
amplicons in chromatin from hippocampus of P90 mice by chromatin 906 
immunoprecipitation with indicated antibodies. Results are expressed as percent input. 907 
**P < 0.01, *P < 0.05 vs. vehicle-treated WT mice, ##P < 0.01, #P < 0.05 vs. 908 
vehicle-treated AtrxΔE2 mice by one-way ANOVA with Bonferroni's post hoc test; n = 6 909 
mice each. Full-size scans of western blots shown in Supplementary Fig. 13. 910 
 911 
 912 
Figure 5. Treatment with 5-ALA counteracts cognitive deficits seen in AtrxΔE2 mice. 913 
a, (top) Representative kymograph of movement of GFP-CaMKIIα 3′ UTR in a 914 
proximal dendrite. Scale bars, 5μm (x-axis) and 5min (y-axis). (bottom) Relative 915 
frequency of movement of GFP-CaMKIIα 3′ UTR granules. Cells were treated with 916 
5-ALA (1μM) for 7 days before imaging. *P < 0.05 vs. vehicle-treated WT neurons, 917 
##P < 0.01 vs. vehicle-treated AtrxΔE2 neurons by two-way ANOVA with Bonferroni's 918 
post hoc test; n = 5 neurons each, a proximal dendrite (20-100μm away from the cell 919 
body) per neuron to measure relative frequencies. Imm., immobile; Bidirect., 920 
bidirectional movement; Antero., anterograde movement; and Retro., retrograde 921 
movement. b, The number of GFP-CaMKIIα 3′ UTR (green) and PSD95 (magenta) 922 
double-positive puncta in a proximal dendrite. **P < 0.01 vs. vehicle-treated WT 923 
neurons, ##P < 0.01 vs. vehicle-treated AtrxΔE2 neurons by one-way ANOVA with 924 
Bonferroni's post hoc test; n = 20 neurons each, a proximal dendrite per neuron. 925 
Whiskers represent minima and maxima. c, (left) Representative field excitatory 926 
post-synaptic potentials (fEPSPs) were recorded from the hippocampal CA1 region of 927 
mice. (middle) Changes in fEPSP slope recorded following high frequency stimulation 928 
(HFS) were attenuated in AtrxΔE2 mice, and 5-ALA treatment significantly rescued 929 
impaired LTP in hippocampal CA1. (right) fEPSP slope changes following HFS at 1 or 930 
60 min, as shown at left. **P < 0.01, *P < 0.05 vs. vehicle-treated WT mice, ##P < 0.01, 931 
#P < 0.05 vs. vehicle-treated AtrxΔE2 mice by two-way ANOVA with post hoc 932 
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Bonferroni's multiple comparison test; WT + vehicle, AtrxΔE2 + vehicle, and AtrxΔE2 + 933 
5-ALA, n = 8 mice; WT + 5-ALA, n=6 mice. d-f, 5-ALA treatment decreased cognitive 934 
deficits in AtrxΔE2 mice based on memory-related tests. Novel-object recognition (NOR) 935 
test (d), latency time in retention trials in a passive avoidance (PA) test (e), and 936 
alternations in a Y-maze test (f). **P < 0.01 vs. vehicle-treated WT mice, ##P < 0.01, 937 
#P < 0.05 vs. vehicle-treated AtrxΔE2 mice by one-way ANOVA with Bonferroni's post 938 
hoc test; Respective sample sizes are indicated. g, Heat map summarizing expression 939 
data (left), and a list of rescued or not-rescued genes (right) between WT, AtrxΔE2, and 940 
5-ALA treated AtrxΔE2 mouse hippocampus at post-natal day (P) 90. The list was 941 
focused on 31 genes differentially expressed (8 up-regulated and 23 down-regulated) in 942 
WT versus AtrxΔE2 samples in Supplementary Table 1 (an FDR < 0.05 and a log2 943 
fold-change of > 0.5 or < 0.5). See also Supplementary Table 3, which includes 944 
5-ALA treated AtrxΔE2 group. Rescued or not rescued genes were assessed using the 945 
difference between the average value in log2 global normalization. WT, n=7 mice; 946 
AtrxΔE2, n=7 mice; AtrxΔE2 + 5-ALA, n=4 mice. Full-size scans of western blots shown 947 
in Supplementary Fig. 13.  948 
  949 
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On-line Methods 950 
 951 
Animals 952 
Male mice (C57BL/6J) were used for all experiments. Mice were housed under 953 
climate-controlled conditions with a 12-h light/dark cycle and provided standard food 954 
and water ad libitum. Animal studies were conducted in accordance with the Tohoku 955 
University institutional guidelines. Ethical approval has been obtained from the 956 
Institutional Animal Care and Use Committee of the Tohoku University Environmental 957 
and Safety Committee. Generation of homozygous AtrxΔE2 mice is described in 19. To 958 
generate Thy1-Xlr3b TG mice, Xlr3b cDNA was subcloned into the XhoI site of a 959 
mouse Thy1.2 expression cassette (Supplementary Fig. 9a). The Thy1 promoter 960 
construct was a gift of Joshua Sanes (Addgene plasmid # 20736). The Thy1.2-Xlr3b 961 
expression cassette was excised with NotI/PvuI and injected into fertilized eggs of B6 962 
mice at Oriental Bio Service (Kyoto, Japan). Hemizygous Thy1-Xlr3b TG mice were 963 
generated by mating founder mice with B6 mice, and offspring were screened by PCR 964 
using genomic tail DNA. Primers used for amplification of Xlr3b sequences were 965 
ThXl(FW) (5′-GGTATTCATCATGTGCTCCG-3′) and ThXl(RV) 966 
(5′-GTTTCTGCCTCTCTTCACAG-3′), and the detected PCR product was 479 bp in 967 
founder animals (Supplementary Fig. 9b).  968 
 969 
Cell culture 970 
Neuro-2a mouse neuroblastoma cells (ATCC, CCL-131, authenticated by the 971 
provider using short tandem repeat profiling) were grown in Dulbecco's minimal 972 
essential medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum 973 
(FBS) and penicillin/streptomycin (100units/100μg/ml) in a 5% CO2 incubator at 37°C. 974 
Cells were routinely tested for mycoplasma contamination. Transfection was performed 975 
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) transfection reagent 976 
according to the manufacturer's protocol. Primary cultures of neurons were established 977 
using previously described methods with slight modifications 56. Briefly, hippocampal 978 
tissue was dissected from embryonic day 18 mice and dissociated by trypsin treatment 979 
and trituration through a Pasteur pipette. Neurons were plated on coverslips coated with 980 
poly-L-lysine in Minimum Essential Medium (Invitrogen) supplemented with 10% FBS, 981 
0.6% glucose (Wako, Osaksa, Japan), and 1mM pyruvate (Sigma-Aldrich, St. Louis, 982 
MO, USA). After cell attachment, coverslips were transferred to dishes containing a 983 
glial cell monolayer and maintained in Neurobasal medium (Invitrogen) containing 2% 984 
B27 supplement (Invitrogen) and 1% GlutaMax (Invitrogen). 5μM Cytosine 985 
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β-D-arabinofuranoside (Sigma-Aldrich) was added to cultures at DIV3 after plating to 986 
inhibit glial proliferation. Primary neurons were transfected with expression vectors and 987 
shRNAs using electroporation (NEPA21; NEPAGENE Co., Ltd. Chiba, Japan) at DIV0. 988 
 989 
Plasmid constructs and lentiviral transduction 990 
Plasmids expressing cDNAs encoding Xlr3a, Xlr3b, FAM9A, DNMT1, 991 
DNMT3A, H3.3 and DAXX were obtained from Kazusa DNA Research Institute 992 
(Promega, Madison, WI, USA) and cDNAs were inserted into pCMV vector. 993 
GST-Xlr3b was generated by cloning Xlr3b cDNA into pGEX-4T-1 (Pharmacia Biotech, 994 
Piscataway, NJ, USA). ATRX cDNA plasmid (pEGFP-C2-ATRX-HA) was kindly 995 
provided by Dr. David Picketts (University of Ottawa, Canada). ATRX shRNA 996 
(pSUPER-shATRX1) plasmid was kindly provided by Dr. Nathalie Berube (University 997 
of Western Ontario, Canada). GFP-MS2-nls and MS2 binding site (MS2bs)-CaMKIIα 998 
3′UTR constructs were kindly provided by Dr. Kenneth S. Kosik (University of 999 
California Santa Barbara Santa Barbara, USA). Xlr3b shRNA was purchased from 1000 
Sigma-Aldrich (MISSION TRC-Mm2.0 TRCN0000255204). The non-targeting hairpin 1001 
control SHC002 (Sigma-Aldrich), which containing a sequence that does not target any 1002 
known human or mouse gene, was used as a negative control (shControl). FLAG-Xlr3b 1003 
(FL, ΔNLS, Δ74-123, Δ124-200, and Δ158-170) and FLAG-FAM9A (FL and Δ292-304) 1004 
were generated using the KOD-Plus Mutagenesis kit (Toyobo, Osaka, Japan) according 1005 
to the manufacturer's protocol. For construction of Xlr3b promoter plasmids, genomic 1006 
DNA isolated from mouse brain was obtained using a DNeasy Tissue Kit (Qiagen, 1007 
Valencia, CA, USA). PCR was carried out to amplify a fragment containing the Xlr3b 1008 
promoter region from nucleotides − 2085 to +1 (where +1 is the A of the translation 1009 
initiation codon). The fragment was then subcloned into the pGL3-basic luciferase 1010 
reporter (Promega) vector (pGL3-2K) and sequenced. pGL3-2KΔG4 and 1011 
pGL3-1KΔCGI were generated using the KOD-Plus Mutagenesis kit (Toyobo). The 1012 
CRISPR-Cas9 and GFP fusion protein expression lentivirus, U6gRNA-Cas9-2A-GFP 1013 
plus guide Xlr3 sgRNA (Xlr3-Cas9-GFP), was purchased from Sigma-Aldrich. The 1014 
Xlr3 guide sequence was TCATCTTTCAGTGCCATGG. Lentiviral transduction was 1015 
performed according to the manufacturer's protocol (Sigma-Aldrich). 1016 
 1017 
Antibodies and peptides 1018 
The following primary antibodies were used; anti-Xlr3 (1:500, generated 1019 
commercially (MBL, Nagoya, Japan) against TDTAGRHSRMDPNLSSDC peptide, 1020 
anti-ATRX (1:100, Santa Cruz Biotechnology, H300 #sc-15408, Santa. Cruz, CA, USA), 1021 
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anti-DNMT1 (1:1000, clone 60B1220.1, Abcam #ab13537, Cambridge, UK), 1022 
anti-DNMT3A (1:1000, clone 64B1446, Abcam #ab13888), anti-β-tubulin (1:5000, 1023 
clone AC-15, Sigma-Aldrich, #A5441), anti-hnRNP A/B (1:200: Santa Cruz 1024 
Biotechnology, G-10 #sc-376411), anti-hnRNP A/B (1:200: Santa Cruz Biotechnology, 1025 
M-15 #sc-82628), anti-DYNC1LI2 (1:1000, clone EPR11230(2), Abcam, #ab178702), 1026 
anti-DYNLL1 (1:200: Santa Cruz Biotechnology, #sc-136287), anti-histone H3.3 1027 
(1:1000, Abcam, #ab62642), anti-DAXX (1:200, Santa Cruz Biotechnology, M-112 1028 
#sc-7152), anti-hnRNP D (1:200, clone D6O4F, Cell Signaling Technology, Beverly, 1029 
MA, USA, #12382), anti-TIA1 (1:200, Santa Cruz Biotechnology, C-20, #sc-1751), 1030 
anti-FLAG (1:1000, clone M2, Sigma-Aldrich, #F1804), anti-synaptophysin (1:1000, 1031 
clone SVP-38, Sigma-Aldrich, #S5768), anti-MAP2 (1:10000, Abcam, #ab92434), 1032 
anti-RNA polymerase II (1:1000, clone CTD4H8, Millipore, MA, USA, #05-623), 1033 
anti-PSD95 (1:500, clone 6G6-1C9, Abcam, #ab2723), anti-phospho-CaMKII 1034 
(Thr286/Thr287, 1:5000, 18) and anti-CaMKIIα/β (1:5000, 18). For immunoblotting, the 1035 
following secondary antibodies were used: anti-mouse IgG antibody horseradish 1036 
peroxidase conjugated (1:5000, Southernbiotech, Birmingham, AL, USA, #1031-05), 1037 
anti-rabbit IgG antibody horseradish peroxidase conjugated (1:5000, Southernbiotech, 1038 
#4050-05) and anti-goat IgG antibody horseradish peroxidase conjugated (1:5000, 1039 
Rockland Immunochemicals Inc., Limerick, PA, USA, #605-4302). For 1040 
immunocytochemistry and immunohistochemistry, the following secondary antibodies 1041 
were used: Alexa488-conjugated donkey anti-rabbit (1:500, Invitrogen, #A-21206) 1042 
Alexa594-conjugated donkey anti-rabbit (1:500, Invitrogen, #A-21207), Alexa 1043 
488-conjugated donkey anti-mouse (1:500, Invitrogen, #A-21202), Alexa 1044 
594-conjugated donkey anti-mouse (1:500, Invitrogen, #A-21203), Alexa 1045 
488-conjugated donkey anti-goat (1:500, Invitrogen, #A-11055), Alexa 594-conjugated 1046 
donkey anti-goat (1:500, Invitrogen, #A-11058) and DyLight 405-AffiniPure donkey 1047 
anti-chicken IgY (1:500; Jackson ImmunoResearch, West Grove, PA, USA, 1048 
#703-475-155). XIP and ANTP control peptides were obtained from the 1049 
peptide-synthetic service at MBL.  1050 
 1051 
Luciferase assay  1052 
Neuro-2a cells were co-transfected with pGL3 plasmids (pGL3-2K, 1053 
pGL3-2KΔG4 and pGL3-1KΔCGI) plus a pRL-TK plasmid, which contains Renilla 1054 
luciferase under control of the herpes simplex virus thymidine kinase promoter, with or 1055 
without other plasmids (ATRX, ATRX shRNA, control shRNA, DNMT1, DNMT3A, 1056 
H3.3 or DAXX). For in vitro DNA methylation assays, pGL3 plasmids were incubated 1057 
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with 3U CpG methyltransferase (M.SssI) (New England Biolabs, Hitchin, UK) for 4h at 1058 
37°C in the presence of 1mM S-adenosylmethionine, following the manufacturer’s 1059 
instructions. Firefly and Renilla luciferase activities were measured using the 1060 
Dual-Luciferase Reporter Assay System (Promega) with a luminometer (Gene Light 55 1061 
Luminometer, Microtech, Chiba, Japan). The ratio of Firefly to Renilla luciferase 1062 
luminescence was calculated. 1063 
 1064 
Identification of Xlr3 interaction proteins by mass spectrometry 1065 
Mouse brain tissues at P60 were lysed in buffer containing 50 mM Tris-HCl (pH 1066 
7.5), 0.15 M NaCl, 0.1% Triton X-100, 4 mM EDTA, 4 mM EGTA, 1 mM Na3VO4, 50 1067 
mM NaF, 1 mM DTT, and protease inhibitors (trypsin inhibitor, pepstatin A, and 1068 
leupeptin), followed by centrifugation at 15,000 × g for 10 min. Supernatants were 1069 
collected and incubated with Protein A Sepharose column (Protein A HP SpinTrap, GE 1070 
Healthcare Life Sciences, Piscataway, NJ, USA) with TBS buffer (50 mM Tris-HCl, 1071 
0.15 M NaCl, pH 7.5) containing an Xlr3 antibody (10 μg) at 4°C for 4 h with constant 1072 
rotation. Bound proteins were then washed with TBS and eluted with 2.5% acetic acid. 1073 
To confirm specific binding, samples were run on SDS-PAGE and the gel was stained 1074 
using a Silver Stain Kit (Wako). All samples were then analyzed by LC-MS/MS at 1075 
Oncomics Co., Ltd, (Nagoya, Japan), as a custom service. Proteins identified in control 1076 
samples pulled down with rabbit IgG (10 μg) were subtracted from identified proteins. 1077 
 1078 
Preparation of proteins binding to GST-Xlr3b  1079 
Preparation of proteins was performed using a GST Protein Interaction 1080 
Pull-Down Kit (Pierce; Thermo Fisher Scientific, Rockford, IL, USA) according to the 1081 
manufacturer’s instructions. GST and GST-Xlr3b were prepared in E. coli BL21 and 1082 
immobilized to glutathione affinity resin. Mouse hippocampal tissues were lysed in 1083 
buffer containing 50 mM Tris-HCl (pH 7.5), 0.15 M NaCl, 4 mM EDTA, 4 mM EGTA, 1084 
1 mM Na3VO4, 50 mM NaF, 1 mM DTT, and protease inhibitors (trypsin inhibitor, 1085 
pepstatin A, and leupeptin), followed by centrifugation and incubation with 1086 
immobilized glutathione affinity resin containing GST fusion proteins at 4°C for 4 h 1087 
with constant rotation. Bound proteins were then washed, eluted with glutathione 1088 
elution buffer, and run on SDS-PAGE. 1089 
 1090 
Immunoprecipitation and immunoblotting  1091 
Immunoprecipitation and immunoblotting analysis was performed as described 1092 
56. Briefly, tissues or cells were homogenized in buffer containing 50 mM Tris-HCl, pH 1093 
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7.5, 0.5% Triton X-100, 0.15 M NaCl, 4 mM EDTA, 4 mM EGTA, 1 mM Na3VO4, 50 1094 
mM NaF, 1 mM DTT, and protease inhibitors (trypsin inhibitor, pepstatin A, and 1095 
leupeptin). For immunoprecipitation, lysates were incubated 2 h at 4°C with indicated 1096 
antibodies with protein A-Sepharose CL-4B (GE Healthcare Life Sciences) in 1097 
homogenization buffer. Subsequently, immunoprecipitates were washed three times 1098 
with homogenization buffer, equivalent amounts of protein were electrophoresed on 1099 
SDS-PAGE and proteins then transferred to an Immobilon polyvinylidene difluoride 1100 
membrane. After blocking with TTBS solution (50 mM Tris–HCl, pH 7.5, 150 mM 1101 
NaCl, and 0.1% Tween 20) containing 5% fat-free milk powder for 1 h at room 1102 
temperature, membranes were incubated overnight at 4 °C with indicated primary 1103 
antibodies. After washing, membranes were incubated with the appropriate horseradish 1104 
peroxidase-conjugated secondary antibody diluted in TTBS. Blots were developed using 1105 
an ECL immunoblotting detection system (Amersham Biosciences, NJ, USA). 1106 
Immunoreactive bands were visualized using a luminescent image analyzer LAS-4000 1107 
(Fuji Film, Tokyo, Japan) and quantified using Image Gauge version 3.41 (Fuji Film). 1108 
 1109 
Subcellular fractionation.  1110 
Primary hippocampal neurons at DIV21 were homogenized in ice-cold lysis 1111 
buffer containing the following (in mM): sucrose 320, HEPES 4, pH 7.4, EGTA 1, and 1112 
protease inhibitors. The homogenate was centrifuged at 1,000 x g for 10 min at 4°C. 1113 
The supernatant (S1, postnuclear supernatant) was centrifuged again at 12,000 x g for 1114 
15 min to obtain crude synaptosomal fraction (P2). For separating synaptosomal cytosol 1115 
(LS1) and synaptosomal membrane (LP1), the pellet (P2) was hypo-osmotically lysed 1116 
(5% lysis buffer; 95% distilled water containing 5% CHAPS and protease inhibitors) for 1117 
30 min and centrifuged at 100,000 x g for 60 min. The pellet (LP1) was resuspended in 1118 
lysis buffer containing 1% Triton X-100 and sonicated.  1119 
 1120 
Immunocytochemistry and immunohistochemistry  1121 
Immunocytochemistry and immunohistochemistry were performed as described 1122 
56. Briefly, fixed cells or brain slices with 4% paraformaldehyde in phosphate-buffered 1123 
saline (PBS) were treated with PBS containing 0.1% Triton X-100 for 10 min. Samples 1124 
were incubated overnight at 4°C with indicated primary antibodies and then washed in 1125 
PBS and incubated with appropriate secondary antibodies. Nuclei were stained with 4, 1126 
6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich). To visualize RNA molecules, 1127 
living neurons were incubated with 50 nM SYTO14 dye (Life Technologies, Carlsbad, 1128 
CA, USA, #S7576). Fluorescence intensities and images were analyzed by confocal 1129 
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laser scanning microscopy (LSM700, Carl Zeiss, Thornwood, NY).  1130 
 1131 
Live imaging  1132 
Live images of granule movement were captured in dendrites for 15 min 1133 
(proximal dendrites) or 10 min (distal dendrites) at 15-s intervals in primary neurons at 1134 
DIV21. Granule movement was analyzed in proximal dendrites (20-100μm) and in 1135 
distal dendrites (100-200μm) away from the cell body. Relative frequency of movement 1136 
of GFP-CaMKII 3′ UTR granules was analyzed for a subset of moving granules. 1137 
Granules that changed direction during the tracking period were defined as 1138 
bi-directional. Granules were classified as immobile when their movement was < 5 μm 1139 
during the 15 min (proximal dendrites) or 10 min (distal dendrites) observation period. 1140 
Kymographs were created using NIH ImageJ software (http://rsb.info.nih.gov/ij/).   1141 
 1142 
RT-PCR and quantitative RT-PCR (RT-qPCR) analysis 1143 
Total RNA was purified from P90 mouse brain using an RNeasy Mini Kit 1144 
(Qiagen) according to the manufacturer’s protocol. RNA was reverse-transcribed into 1145 
single-stranded cDNA using an oligo(dT) primer (Promega) and Moloney murine 1146 
leukemia virus-reverse transcriptase (Invitrogen), and then subjected to RT-PCR with 1147 
gene-specific primers. RT-qPCR analysis was performed as described 18 in 48-well 1148 
plates (Mini Opticon real-time PCR system, Bio-Rad) using iQ SYBR Green Supermix 1149 
2× (Bio-Rad). Gene expression was assessed using the differences in normalized Ct 1150 
(ΔΔCt) method after normalization to GAPDH. Fold-change was calculated by 2-ΔΔCt. 1151 
The following primers were used for RT-PCR and RT-qPCR:  1152 
In Fig. 1b, Fig. 4d, supplementary Fig. 1e, supplementary Fig. 9c, and supplementary 1153 
Fig.10c. 1154 
RT-qPCR-Xlr3b(FW) (5′-CAGAAAAAGGAAGGCCACTG-3′)  1155 
RT-qPCR-Xlr3b(RV) (5′- GTTTTTCCTTCCTGGCCTGT -3′)  1156 
RT-qPCR-GAPDH(FW) (5′-TGTGTCCGTCGTGGATCTGA-3′)  1157 
RT-qPCR-GAPDH(RV) (5′-CACCACCTTCTTGATGTCATCATAC-3′) 1158 
In supplementary Fig. 1a, 1159 
RT-PCR-Xlr3a(FW) (5′-AGCCGAGACCCGACCAAGTGG-3′)  1160 
RT-PCR-Xlr3a(RV) (5′-TGTTAGCTGGGTTCTG-3′)  1161 
RT-PCR-Xlr3b(FW) (5′-AGCCAAGGCCCGACCAAGTGG-3′) 1162 
RT-PCR-Xlr3b(RV) (5′-TAGCTGCTGCGACTGCACCT-3′) 1163 
 1164 
Bisulphite sequencing 1165 
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Genomic DNA isolated from whole brain, medial prefrontal cortex and 1166 
hippocampus of WT and AtrxΔE2 mice at P90 were subjected to bisulphite-mediated C to 1167 
U conversion using BisulFast (Toyobo, Osaka, Japan) and then used as template for 1168 
PCR. The PCR products were ligated into the pCR2.1 vector by using a TOPO-TA 1169 
cloning kit (Invitrogen), according to the manufacturer's instruction. The following 1170 
primers specific for bisulfite-treated DNA were used for PCR:  1171 
Xlr-bisul(FW) (5′-GATTAAGTGGGATGAATTTTTGAGT-3′) 1172 
Xlr-bisul(RV) (5′-CCCAAACTAAAAATTTTTCTCATTC-3′) 1173 
 1174 
Chromatin immunoprecipitation (ChIP) assay 1175 
Chromatin solutions derived from P90 mouse hippocampus were prepared using 1176 
the SimpleChIP Plus Enzymatic Chromatin IP Kit (Cell Signaling Technology) and then 1177 
immunoprecipitated overnight at 4°C using 2 μg indicated antibodies. Assays included 1178 
normal rabbit IgG as an antibody specificity control. The following antibodies and 1179 
primers were used:  1180 
in Fig. 1  1181 
R1(FW) (5′-CCAAGTGGGATGAACCTCTGAGTG-3′)  1182 
R1(RV) (5′-CCGCGGAGTCCCACTGTGGAACGT-3′)  1183 
R2(FW) (5′-CACAAGTACTATACTAGCTGAAAC-3′)  1184 
R2(RV) (5′-GGTTGGTCATACCTATGTAGGAAC-3′) 1185 
in Fig. 4 1186 
amplicon 1(FW) (5′-CCAAGTGGGATGAACCTCTGAGTG-3′)  1187 
amplicon 1(RV) (5′-CCGCGGAGTCCCACTGTGGAACGT-3′)  1188 
amplicon 2(FW) (5′-GCCACAGAGGGCAAGGCAAGGGAG-3′) 1189 
amplicon 2(RV) (5′-AATGATGTCTTGGTTGGGAATTCCA-3′) 1190 
amplicon 3(FW) (5′-AGTATCAGGCTTAGATTTAAAGGA-3′) 1191 
amplicon 3(RV) (5′-AAGTCAGGGAGGATGACCAGTCTC-3′) 1192 
amplicon 4(FW) (5′-CTGTGCGGGACTCCCATGATACCC-3′) 1193 
amplicon 4(RV) (5′-CGTAAGCCCTTCAGCATAAATACT-3′) 1194 
 1195 
RNA immunoprecipitation (RIP) assay 1196 
Mouse hippocampal lysates were immunoprecipitated with an Xlr3 antibody (15 1197 
μg per sample) followed by RNA isolation using the RiboCluster Profiler RIP-Assay kit 1198 
(MBL) according to the manufacturer's protocols. Immunoprecipitated RNA was 1199 
reverse-transcribed into single-stranded cDNA using an oligo(dT) primer (Promega) and 1200 
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Moloney murine leukemia virus-reverse transcriptase (Invitrogen), and subjected to 1201 
RT-qPCR with the following gene-specific primers:  1202 
BDNF(FW) (5′-TGGCCTAACAGTGTTTGCAG-3′) 1203 
BDNF(RV) (5′-GGATTTGAGTGTGGTTCTCC-3′)  1204 
CaMKIIα(FW) (5′-GACACCAAAGTGCGCAAACAGG-3′)  1205 
CaMKIIα(RV) (5′-GCGAAGCAAGGACGCAGG-3′)  1206 
Arc(FW) (5′-AGCAGCAGACCTGACATCCT-3′)  1207 
Arc(RV) (5′-GGCTTGTCTTCACCTTCAGC-3′) 1208 
GAPDH(FW) (5′-TGTGTCCGTCGTGGATCTGA-3′)  1209 
GAPDH(RV) (5′-CACCACCTTCTTGATGTCATCATAC-3′) 1210 
 1211 
Gene microarray analysis  1212 
For the oligo-DNA microarray analysis, we used the “3D-Gene” Mouse Oligo 1213 
chip 24k and Human Oligo chip 25k arrays (Toray Industries Inc, Tokyo, Japan). Total 1214 
RNA was purified from mouse hippocampus using an RNeasy Mini Kit (Qiagen) 1215 
according to the manufacturer’s instructions. Total RNA was Cy5-labeled using the 1216 
Amino Allyl MessageAMP II aRNA Amplification Kit (Applied Biosystems, CA, 1217 
USA). Labeled aRNA pools were then hybridized 16 h in buffer using the supplier's 1218 
protocols (www.3d-gene.com). Hybridization signals were scanned using a ScanArray 1219 
Express Scanner (PerkinElmer) and processed using the GenePixPro version 5.0 1220 
software (Molecular Devices).  1221 
 1222 
Electrophysiology 1223 
Preparation of hippocampal slices was performed as described 19. Briefly, brains 1224 
were rapidly removed from ether-anesthetized mice and chilled in ice-cold oxygenated 1225 
artificial cerebrospinal fluid (ACSF: 126 mM NaCl, 5 mM KCl, 26 mM NaHCO3, 2.4 1226 
mM CaCl2, 1.3 mM MgSO4, 1.26 mM KH2PO4, and 10 mM D-glucose). Transverse 1227 
hippocampal slices (400-μm thickness) were cut using a vibratome (Microslicer 1228 
DTK-1000, Dosaka EM, Kyoto, Japan) and transferred to a recording chamber where 1229 
they were allowed to recover at least 1 h at 34°C before recording. ACSF maintained at 1230 
34°C was used during the experiment. A concentric bipolar stimulating electrode was 1231 
placed in the stratum radiatum of CA1 to stimulate the Schaffer collateral pathway. 1232 
High-frequency stimulation of 100 Hz with 1-s duration was applied twice with a 20-s 1233 
interval. Traces were digitized with an A/D converter (PowerLab 200; AD Instruments, 1234 
Castle Hill, Australia) and a computer (Windows, Measurement and Analysis System 1235 
for LTP: FAL-3000). Paired-pulse responses were measured with inter-stimulus 1236 
38 
 
intervals of 20-500 ms and expressed as the ratio of second stimulated amplitude to the 1237 
first stimulated amplitude. The hippocampal input/output (I/O) ratio was determined for 1238 
each group by measuring fEPSP amplitude in response to a series of stimuli with 1239 
intensities ranging from 0.1 to 1.1 mA. After recording, slices were transferred to a 1240 
plastic plate on ice to dissect the CA1 region under a microscope. CA1 regions were 1241 
frozen in liquid nitrogen and stored at -80°C until biochemical analysis. 1242 
 1243 
Drugs 1244 
5-ALA (COSMO BIO co., ltd. Tokyo, Japan), and sodium ferrous citrate were 1245 
kindly provided by SBI Pharmaceuticals Co., Ltd., (Tokyo, Japan). TMPyP4 (5, 10, 15, 1246 
20-Tetrakis (1-methyl-4-pyridinio)porphyrin tetra) was purchased from Sigma-Aldrich. 1247 
For administration to AtrxΔE2 mice, mice were randomized into 7 groups as follows: 1248 
5-ALA (3 and 10 mg/kg, p.o. with sodium ferrous citrate (20:1 mol. ratio) dissolved in 1249 
distilled water) or vehicle (sodium ferrous citrate dissolved in distilled water) was 1250 
administered daily from P30 to P90. TMPyP4 (10 and 30 mg/kg, i.p. in saline) or 1251 
vehicle (saline) was administered twice weekly from P30 to P90. For acute 1252 
administration, 5-ALA (10 mg/kg, p.o.) was administered 3 h before experiments. 1253 
Measurement of biodistribution in TMPyP4 and 5-ALA was performed as described in 1254 
47, 49. 1255 
 1256 
Behavioral analysis 1257 
Adult male mice at P90 were used for behavioral analysis. Animals were 1258 
subjected to behavioral tests including Y-maze, step-through passive avoidance, novel 1259 
object recognition and social interaction tasks. All behavioral experiments were 1260 
conducted with the experimenter blind to mouse genotypes and treatments. In the 1261 
Y-maze task, spontaneous alternation behavior in a Y-maze was assessed as a task of 1262 
spatial reference memory. The apparatus consisted of three identical arms 1263 
(50×16×32 cm3) of black plexiglas. Mice were placed at the end of one arm and allowed 1264 
to move freely through the maze during an 8-min session. The sequence of arm entries 1265 
was manually recorded. An alternation was defined as entries into all three arms on 1266 
consecutive choices. The maximum number of alternations was defined as the total 1267 
number of arms entered minus two, and the percentage of alternations was calculated as 1268 
actual alternations/maximum alternations×100. The total number of arms entered during 1269 
the session was also determined. In step-through passive avoidance task, training and 1270 
retention trials of passive avoidance tasks were conducted in a box consisting of dark 1271 
(25×25×25 cm3) and light (14×10×25 cm3) compartments. The floor was constructed 1272 
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with stainless steel rods, and rods in the dark compartment were connected to an 1273 
electronic stimulator (Nihon Kohden, Tokyo, Japan). Mice were habituated to the 1274 
apparatus the day before passive avoidance acquisition. During training, a mouse was 1275 
placed in the light compartment, and when it entered the dark compartment, the door 1276 
was closed and an electric shock (0.4 mA for 2 s) was delivered from the floor. The 1277 
mouse was removed from the apparatus 30 s later. After a 7-day interval, each mouse 1278 
was placed in the light compartment and step-through latency was recorded over 300 s 1279 
to assess retention. In the novel object recognition task, mice were individually 1280 
habituated to an open-field box (35×25×35 cm3) for 2 consecutive days. During 1281 
acquisition phase, two objects of the same material were placed symmetrically in the 1282 
center of the chamber for 10 min. 24 h later, one object was replaced by a novel object, 1283 
and exploratory behavior was analyzed again for 5 min. After each session, objects were 1284 
thoroughly cleaned with 70% ethanol to prevent odor recognition. Exploration of an 1285 
object was defined as rearing on the object or sniffing it at a distance of less than 1 cm, 1286 
touching it with the nose, or both. Successful recognition was reflected by preferential 1287 
exploration of the novel object. Discrimination of spatial novelty was assessed by 1288 
comparing the difference between exploratory contacts of novel and familiar objects 1289 
and the total number of contacts with both, making it possible to adjust for differences 1290 
in total exploration contacts. A social interaction test was established using methods 1291 
described in 57 with slight modifications. WT and AtrxΔE2 mice were housed in new 1292 
partitioned cages such that the AtrxΔE2 mouse occupied one compartment and a 1293 
weight-matched WT mouse (non-littermate) occupied the other. Forty-eight hours later, 1294 
the partition was removed and social interaction between mice was videotaped for 1295 
10 min. Scored behaviors were divided into four groups. Active social behavior, 1296 
initiated by the experimental mouse toward the partner, includes: (1) sniffing of any part 1297 
of partner's body including the anogenital area; (2) following including direct aggressive 1298 
attacks accompanied by bites toward the partner's back. Passive social behavior, which 1299 
occurs as a reaction to active behavior of the partner toward the experimental mouse, 1300 
includes (3) receptive responses when the experimental mouse tolerates sniffing by the 1301 
partner but shows no defensive or submissive behavior, (4) escape in response to a 1302 
partner's following or aggressive act. Data were analyzed as percentage of time spent in 1303 
various social behaviors during a 10-min interaction test. The videotapes for all 1304 
behavioral analysis were scored by a trained observer blind to genotype and treatment. 1305 
 1306 
Actin assays 1307 
An in vitro F-actin sedimentation assay was performed using the Actin Binding 1308 
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Protein Spin Down Assay (nonmuscle) kit (BK013; Cytoskeleton, Inc., Denver, CO, 1309 
USA). Briefly, recombinant Xlr3b protein (1μM) purified from E. coli or α-actinin were 1310 
mixed with polymerized nonmuscle actin (10μM) and incubated 30 min at 22°C. 1311 
Mixtures were centrifuged to sediment F-actin, and supernatant and pellet fractions 1312 
were analyzed by SDS–PAGE, followed by Silver staining. Actin polymerization was 1313 
measured using a pyrene-actin polymerization kit (BK003, Cytoskeleton, Inc.) 1314 
following the manufacturer's instructions. 1315 
 1316 
CD spectra 1317 
All oligonucleotides were purchased from Sigma-Aldrich without further 1318 
purification. Oligonucleotides for CD spectra were prepared in Li+ solution or K+ 1319 
solution (20 mM lithium cacodylate, pH 7.0, 10 or 100 mM KCl). Annealing was 1320 
performed by heating to 95°C for 5 min and cooling down slowly to room temperature. 1321 
CD spectra were measured in 0.5-nm steps from 340 to 220 nm using a JASCO 1322 
J-805LST Spectrometer and 1-cm quartz cuvettes. 1323 
 1324 
UV melting experiment 1325 
UV–Vis melting temperature analyses were performed on a V-650 1326 
spectophotometer (JASCO, Japan) with a thermocontrolled PAC-743R cell changer 1327 
(JASCO, Japan) and a refrigerated and heating circulator F25-ED (Julabo). 1328 
Oligonucleotides (ODN) (5 μM) in K+ solution (20 mM lithium cacodylate, pH 7.0, 5 1329 
mM KCl) and 1 eq compounds were added. Annealing was performed by heating to 1330 
95°C for 5 min and slowly cooling to room temperature. Melting temperature (Tm) of 1331 
each sample was measured at 295 nm from 15 to 95°C at a rate of 1.0 °C /min. ΔTm was 1332 
calculated using Tm values of samples with and without compounds.  1333 
 1334 
Gel electrophoresis 1335 
DNA samples (ODN) for gel electrophoresis were prepared similarly to CD 1336 
spectra samples. Annealing was performed by heating to 95°C for 5 min and cooling 1337 
slowly to room temperature. Each sample was analysed by native gel (8%) in 1×TBE 1338 
buffer containing 10 or 100 mM KCl at room temperature. Single-stranded DNA was 1339 
stained with SYBR® Green I Nucleic Acid Stain (50513, Lonza, Japan). Gels were then 1340 
imaged by FLA-3000 (FUJIFILM).  1341 
 1342 
DMS footprinting 1343 
Samples (ODN) for DMS footprinting were prepared similarly to samples of CD 1344 
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spectra. DNA samples (10 μL) were then mixed with 1 μL of dimethyl sulfate solution 1345 
(DMS:ethanol; 4:1, vol/vol). Reactions were quenched with 9 μL stop buffer (3 M 1346 
-mercaptoethanol:water:NaOAc; 1:6:7, vol/vol). After ethanol precipitation and 1347 
piperidine cleavage, reactions were separated on 12% denaturing polyacrylamide gels 1348 
using a Hitachi DNA sequencer. Electrophoresis was conducted under 1.5 kV, ca. 25 1349 
mA, and 40°C. 1350 
 1351 
Statistical analysis 1352 
To determine the sample size in our experiments, we followed the standard 1353 
sample sizes used in similar experiments in each of the relevant fields in the literature. 1354 
All values were expressed as means ± s.e.m. Comparisons between two experimental 1355 
groups were made using the two-sided unpaired t test. Statistical significance for 1356 
differences among groups was tested by one-way or two-way ANOVA with post-hoc 1357 
Bonferroni's multiple comparison test. P < 0.05 was considered significant. All the 1358 
statistical analyses were performed using GraphPad Prism 7 (GraphPad Software, Inc., 1359 




  1364 
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Figure legends (for Supplementary materials only) 1377 
 1378 
Supplementary Fig. 1. Identification of Xlr3b in mouse brain. a, Sequence of 1379 
Xlr3a/Xlr3b mRNA and position of PCR primers. b, Xlr3a and Xlr3b primer specificity 1380 
was confirmed by amplifying respective cDNAs. Serial dilutions of cDNA were 1381 
prepared and Q-PCR performed. A negative correlation was found between increasing 1382 
concentrations of cDNA and Ct. The R squared value (coefficient of determination, R2) 1383 
was used to determine amplification efficiency. The experiments were repeated twice 1384 
with similar results. c, Xlr3a and Xlr3b mRNA levels in mouse brain tissue as 1385 
determined by RT-PCR. Xlr3a (lane 1) and Xlr3b (lane 2) cDNAs served as positive 1386 
controls. W, wild-type mice; A, AtrxΔE2 mice; PC, prefrontal cortex; HP, hippocampus; 1387 
HT, hypothalamus; CE, cerebellum. d, Cultured hippocampal neurons were transduced 1388 
with U6gRNA-Cas9-2A-GFP plus guide Xlr3 sgRNA (Xlr3-Cas9-GFP) lentivirus (top) 1389 
or control lentivirus expressing GFP (bottom) and immunostained 21 days later. 1390 
Confocal images revealed loss of Xlr3 (red) immunoreactivity in MAP2-positive (blue) 1391 
neurons infected with Xlr3-Cas9-GFP but not control GFP virus. In c and d, the 1392 
experiments were repeated three times with similar results. e, Quantitative real-time 1393 
RT-PCR showing Xlr3b mRNA expression in cells shown in d. **P < 0.01 by 1394 
two-sided unpaired t-test. n = 4 biologically independent samples. f, Immunoblot (left) 1395 
and corresponding quantitative (right) analysis of Xlr3 protein in cells shown in d. 1396 
Densitometric analysis of Xlr3 normalized to β-tubulin (arbitrary units, A.U.). **P < 1397 
0.01 by two-sided unpaired t-test. n = 5 biologically independent samples.  1398 
 1399 
Supplementary Fig. 2. Bisulfite sequencing evaluation of Xlr3 CGI methylation in 1400 
AtrxΔE2 mouse brain lysates. a, (top) Schematic showing clusters of Xlr genes on the 1401 
C57BL/6J X chromosome. See also Raefski and O'Neill, (2005) 23. (bottom) Location of 1402 
Xlr3 CpG sites analyzed. Sequences potentially forming G-quadruplex is shaded in gray. 1403 
b, Methylation status of Xlr3 CpG sites. Open circles, unmethylated CpGs; closed 1404 
circles, methylated CpGs. Male P90 mice were used. n = 3 mice each. 4 independent 1405 
clones of each sample were sequenced. Roman numerals correspond to those of the 1406 
CpG sites shown in a and b. 1407 
 1408 
Supplementary Fig. 3. G-quadruplex formation by sequences of Xlr3b CGI 1409 
(Xlr3b-ODN). a, CD spectra of Xlr3b-ODN in Li+ or K+ solutions. b, Xlr3b-ODN 1410 
primarily formed intramolecular, parallel G-quadruplexes based on native gel 1411 
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electrophoresis. c, DMS footprinting of G-quadruplexes formed on Xlr3b-ODN in the 1412 
Li+ or K+ solutions. In a-c, the experiments were repeated twice with similar results. 1413 
 1414 
Supplementary Fig. 4. ATRX interacts with DAXX, DNMT1, DNMT3A and H3.3 1415 
in mouse hippocampus. a, Effect of ATRX shRNA in Neuro-2a cells. Immunoblot 1416 
analysis (left) and densitometric quantification (right) of protein expression. 1417 
Densitometric analysis of ATRX normalized to β-tubulin (arbitrary units, A.U.). **P < 1418 
0.01 by two-sided unpaired t-test. n = 3 biologically independent samples. b, (left) 1419 
Representative immunoblot of P90 mouse hippocampal lysates probed with indicated 1420 
antibodies, (right) Quantitative densitometry analyses. **P < 0.01 by two-sided 1421 
unpaired t-test. n = 6 mice each. c, ATRX was immunoprecipitated (IP'd) from P90 WT 1422 
and AtrxΔE2 hippocampal extracts, and western blot analysis performed for indicated 1423 
proteins. Control reactions were performed with IgG. Extracts were assessed as 1% 1424 
input. The experiments were repeated three times with similar results. 1425 
 1426 
Supplementary Fig. 5. Purified Xlr3b protein does not bind F-actin or alter actin 1427 
polymerization. a, F-actin binding assay. Supernatant (S) and pellet (P) fractions were 1428 
collected and samples separated on a SDS-gel subsequently stained using a Silver Stain 1429 
Kit. Reactions were set up as indicated at top. Most α-actinin was found in pellet in the 1430 
presence of F-actin filaments (lanes 9 and 10), while Xlr3b remained in the supernatant 1431 
in presence of F-actin filaments (lanes 5 and 6). b, Actin polymerization as measured by 1432 
enhanced fluorescence of pyrene-conjugated actin. Xlr3b addition to purified actin did 1433 
not alter polymerization. In a and b, the experiments were repeated twice with similar 1434 
results. 1435 
 1436 
Supplementary Fig. 6. Xlr3b co-localizes with hnRNP A/B. a-c, Confocal images 1437 
showing co-localization of FLAG-tagged Xlr3b constructs with hnRNP A/B (a), Dcp1a 1438 
(b) and ubiquitin (c) in Neuro-2a cells. Nuclear DNA is labeled with DAPI (blue). Scale 1439 
bars, 10μm. d, Neuro-2a cells were transfected with FLAG-tagged Xlr3b constructs, 1440 
cell lysates were immunoprecipitated (IP) with anti-FLAG antibody, and western blot 1441 
(WB) was probed with ubiquitin antibody. e, (top) Sequence comparison of Xlr3b 1442 
residues 158-170 and comparable sequences from the Xlr human orthlogs FAM9A and 1443 
FAM9B. Identical AAs are in blue and similar in light green. (bottom), Confocal images 1444 
show localization of FLAG-tagged FAM9A constructs (green) in Neuro-2a cells. 1445 
Nuclear DNA is labeled with DAPI (blue). Scale bars, 10μm. In a-e, the experiments 1446 




Supplementary Fig. 7. Interaction of Xlr3b AA 158-170 and RBPs. a, Diagram of 1449 
permeabilization control peptide (antennapedia homeodomain (ANTP)) and Xlr3b 1450 
inhibitory peptide (XIP). The latter is a 29-AA peptide that contains Xlr3b AA 158-170 1451 
plus ANTP. b, FL-Xlr3b-transfected cells were treated with XIP (1μM for 4h) and 1452 
immunostained for TIA1. Scale bars, 20μm. c, Pull-down assays with an ANTP 1453 
antibody assessing TIA1 and hnRNP A/B in P90 mouse brain lysates. Eluted proteins 1454 
and inputs were immunoblotted with indicated antibodies. Extract samples served as 1% 1455 
input. IP, immunoprecipitation. In b and c, the experiments were repeated three times 1456 
with similar results. 1457 
 1458 
Supplementary Fig. 8. Dynamics of CaMKIIα mRNA transport in distal dendrites. 1459 
a, Confocal images of mCherry-Xlr3b Δ124-200 or Δ158-170 (red) and GFP-CaMKIIα 1460 
3′ UTR (green) in cultured neurons at day 21 in vitro. Scale bars, 10μm. The 1461 
experiments were repeated three times with similar results. b, (top, left) A confocal 1462 
image of GFP-CaMKIIα 3′ UTR in primary mouse cultured neurons at day 21 in vitro. 1463 
Scale bar, 50μm. Images at right is enlarged from corresponding boxed area. Scale bar, 1464 
10μm. See also Supplementary Video 2. (bottom) Relative frequency of movement of 1465 
GFP-CaMKIIα 3′ UTR granules. **P < 0.01 by two-way ANOVA with Bonferroni's 1466 
post hoc test; n = 5 neurons each, a distal dendrite (100-200μm away from the cell 1467 
body) per neuron to measure relative frequencies. Cells were treated with XIP (1μM) 4 1468 
h before imaging. Imm., immobile; Bidirect., bidirectional movement; Antero., 1469 
anterograde movement; and Retro., retrograde movement.  1470 
 1471 
Supplementary Fig. 9. Generation of Thy1-Xlr3b transgenic mice. a, Genomic 1472 
organization of Thy1 gene (top) and the transgenic construct (bottom). The Xlr3b 1473 
cDNA was subcloned into a XhoI site of the Thy1.2 expression cassette. Blue boxes, 1474 
untranslated exons. b, Representative PCR genotyping using tail DNA of transgenic 1475 
founders (#13 and #57). M, size marker. c, Quantitative real-time RT-PCR showing 1476 
Xlr3b mRNA expression in P90 mouse hippocampal lysates. **P < 0.01 by one-way 1477 
ANOVA with Bonferroni's post hoc test; n = 6 mice each. TG, Xlr3b transgenic mouse. 1478 
d, (top) Representative immunoblot of mouse hippocampal lysates probed with Xlr3 1479 
and β-tubulin antibodies, (bottom) Densitometric analysis of Xlr3 normalized to 1480 
β-tubulin (arbitrary units, A.U.). **P < 0.01 by two-sided unpaired t-test; n = 5 mice 1481 
each. e, Effect of Xlr3b shRNA in cultured neurons. Immunoblot analysis (top) and 1482 
densitometric quantification (bottom) of protein expression. Densitometric analysis of 1483 
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Xlr3 normalized to β-tubulin (arbitrary units, A.U.). *P < 0.05 by two-sided unpaired 1484 
t-test; n = 3 biologically independent samples. f, (left) Method for isolation of 1485 
synaptosomal membrane fractions from cultured neurons. The procedure for the 1486 
subcellular fractionation is described in Methods. P1, nucleus/cell debris; S1, 1487 
postnuclear supernatant; S2, cytosol fraction; P2, crude synaptosomal fraction; LS1, 1488 
synaptosomal cytosol fraction; LP1, synaptosomal membrane fraction. Immunoblot 1489 
showing CaMKIIα and postsynaptic marker, PSD95 between S2, LS1, and LP1 in 1490 
cultured neurons from WT mice. (middle and right) Immunoblot and corresponding 1491 
quantitative analysis of CaMKIIα and PSD95 proteins at LP1 and whole cell lysates in 1492 
cultured neurons. Densitometric analyses of CaMKIIα normalized to PSD95 (arbitrary 1493 
units, A.U.). **P < 0.01 by one-way ANOVA with Bonferroni's post hoc test. (In WT 1494 
vs. Xlr3b-TG, **P < 0.01 by two-sided unpaired t-test.) LP1, n = 5 biologically 1495 
independent samples; whole cell lysates, n = 4 biologically independent samples. g, 1496 
(top) Representative field excitatory post-synaptic potentials (fEPSPs) were recorded 1497 
from the hippocampal CA1 region of mice. (left), Changes in fEPSP slope following 1498 
high frequency stimulation (HFS) were attenuated in Xlr3b-TG mice in hippocampal 1499 
CA1. (right), Changes in fEPSP slope following HFS at 1 or 60 min. **P < 0.01 by 1500 
two-way ANOVA with Bonferroni's post hoc test; n = 8 mice each. h, Paired pulse 1501 
facilitation (left) and input-output relationship (right) were recorded. n = 5 mice each. 1502 
There were no significant changes between the groups. i, LTP-induced CaMKIIα 1503 
phosphorylation in the hippocampus. (left) Representative images of immunoblots 1504 
using antibodies against phosphorylated CaMKIIα (pCaMKIIα) and total CaMKIIα. 1505 
(right) Densitometric analysis of pCaMKIIα normalized to total CaMKIIα (arbitrary 1506 
units, A.U.). **P < 0.01, *P < 0.05, vs. WT mice before high-frequency stimulation 1507 
(HFS), ##P < 0.01, #P < 0.05, before HFS vs. after HFS in each group by two-way 1508 
ANOVA with Bonferroni's post hoc test. Respective sample sizes are indicated. j-l, 1509 
Xlr3b-TG mice show memory deficits. Novel-object recognition (NOR) test (j), 1510 
Latency time in retention trials in a passive avoidance (PA) test (k), Alternations in a 1511 
Y-maze test (l) are shown. **P < 0.01, *P < 0.05 by two-sided unpaired t-test. 1512 
Respective sample sizes are indicated. 1513 
 1514 
Supplementary Fig. 10. TMPyP4 treatment inhibits Xlr3b expression. a, The 1515 
binding effect of Protoporphyrin IX (PpIX), hemin and TMPyP4 on G-quadruplexes 1516 
formed by Xlr3b-ODN based on a UV melting experiment. b, Luciferase activity of 1517 
Neuro-2a cells transfected with pGL3-2K or pGL3-2KΔG4 and treated with TMPyP4 (1, 1518 
3, 10, 30 and 100μM) for 48 h. Luciferase activity is shown relative to activity in 1519 
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vehicle-treated cells. **P < 0.01 by one-way ANOVA with Bonferroni's post hoc test; n 1520 
= 3 biological replicates. c, Quantitative real-time RT-PCR showing Xlr3b mRNA 1521 
expression in mouse hippocampal lysates. **P < 0.01 vs. vehicle-treated WT mice, ##P 1522 
< 0.01 vs. vehicle-treated AtrxΔE2 mice by one-way ANOVA with Bonferroni's post hoc 1523 
test; n = 4 mice each. d, (top) Representative immunoblot of mouse hippocampal lysates 1524 
probed with Xlr3 and β-tubulin antibodies, (bottom) Densitometric analysis of Xlr3 1525 
normalized to β-tubulin (arbitrary units, A.U.). **P < 0.01 vs. vehicle-treated WT mice, 1526 
##P < 0.01 vs. vehicle-treated AtrxΔE2 mice by one-way ANOVA with Bonferroni's post 1527 
hoc test; n = 4 mice each. e, Methylation status of Xlr3b CpG sites. Open circles, 1528 
unmethylated CpGs; closed circles, methylated CpGs. Male P90 mice were used. n = 3 1529 
mice each. three independent clones of each sample were sequenced.  1530 
 1531 
Supplementary Fig. 11. TMPyP4 treatment rescues cognitive deficits seen in 1532 
AtrxΔE2 mice. a, Relative frequency of movement of GFP-CaMKIIα 3′ UTR granules in 1533 
distal dendrites. Cells were treated with 5-ALA (1μM) for 7 days before imaging. **P < 1534 
0.01, *P < 0.05 vs. vehicle-treated WT neurons, ##P < 0.01 vs. vehicle-treated AtrxΔE2 1535 
neurons by two-way ANOVA with Bonferroni's post hoc test; n = 5 neurons each, a 1536 
distal dendrite (100-200μm away from the cell body) per neuron to measure relative 1537 
frequencies. Imm., immobile; Bidirect., bidirectional movement; Antero., anterograde 1538 
movement; and Retro., retrograde movement. b, Paired pulse facilitation (left) and 1539 
input-output relationship (right) were recorded. n = 5 mice each. There were no 1540 
significant changes between the groups. c, (left) Immunoblot and corresponding 1541 
quantitative analyses of CaMKIIα and PSD95 proteins at LP1 (synaptosomal membrane 1542 
fractions) and whole cell lysates in cultured neurons. Densitometric analyses of 1543 
CaMKIIα normalized to PSD95 (arbitrary units, A.U.). *P < 0.05 vs. vehicle-treated 1544 
WT neurons, #P < 0.05 vs. vehicle-treated AtrxΔE2 neurons by one-way ANOVA with 1545 
Bonferroni's post hoc test; n = 5 biologically independent samples. (right) LTP-induced 1546 
CaMKIIα phosphorylation in the hippocampus. Representative images of immunoblots 1547 
using antibodies against phosphorylated CaMKIIα (pCaMKIIα) and CaMKIIα. 1548 
Densitometric analysis of pCaMKIIα normalized to total CaMKIIα (arbitrary units, 1549 
A.U.). *P < 0.05, vs. WT mice before high-frequency stimulation (HFS), ##P < 0.01, 1550 
before HFS vs. after HFS in each group by two-way ANOVA with Bonferroni's post 1551 
hoc test; n = 4 mice each. d-f, TMPyP4 treatment rescued cognitive deficits in AtrxΔE2 1552 
mice based on memory-related behavioral tests. Novel-object recognition (NOR) test 1553 
(d), latency time in retention trials in a passive avoidance (PA) test (e), alternations in a 1554 
Y-maze test (f) are shown. **P < 0.01 vs. vehicle-treated WT mice, #P < 0.05, ##P < 1555 
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0.01 vs. vehicle-treated AtrxΔE2 mice by one-way ANOVA with Bonferroni's post hoc 1556 
test; Respective sample sizes are indicated. g, AtrxΔE2 mice show withdrawal in social 1557 
interactions with WT mice. AtrxΔE2 mice showed enhanced passivity, higher escape 1558 
duration and decreased social activity, such as following and sniffing behaviors, in 1559 
social interactions with WT mice. These behaviors are dramatically improved by 1560 
5-ALA treatment. **P < 0.01, *P < 0.05 vs. vehicle-treated WT mice, ## P < 0.01, #P 1561 
< 0.05 vs. vehicle-treated AtrxΔE2 mice by one-way ANOVA with Bonferroni's post hoc 1562 
test; Respective sample sizes are indicated. h, Measurements of TMPyP4 fluorescence 1563 
levels. Chronic intraperitoneal injection of TMPyP4 in P90 mice increased fluorescence 1564 
levels in some tissues, including brain. Respective sample sizes are indicated. i, 1565 
Measurements of body weight following chronic TMPyP4 administration on day 60 (i.p. 1566 
twice weekly from P30 to P90). Respective sample sizes are indicated. j, Measurements 1567 
of 5-ALA levels in P90 mouse brain after oral administration (3mg/kg, p.o.). Respective 1568 
sample sizes are indicated. 1569 
 1570 
Supplementary Fig. 12. Schematic showing outcomes following Atrx mutation. 1571 
ATRX binds to parallel G-quadruplexes in Xlr3b CGIs along with DNMTs, DAXX and 1572 
H3.3, regulating Xlr3b gene expression through DNA methylation in cooperation with 1573 
DMNTs. CaMKIIα mRNA locates in neuronal dendrites, and its transport is 1574 
dynamically regulated by the motor protein, dynein. CaMKIIα translation enhances 1575 
synaptic efficacy postsynaptically, which is critical for learning and memory. In control 1576 
neurons, ATRX binds G-quadruplex-forming DNA in Xlr3b CGIs, inhibiting Xlr3b 1577 
expression through DNA methylation. In Atrx mutant neurons, aberrant expression of 1578 
Xlr3b protein occurs through DNA de-methylation at the site. Xlr3b protein has RNA 1579 
binding capacity and cooperates with RNA binding proteins (RBPs), and inhibits 1580 
dendritic transport of CaMKIIα mRNA, resulting synaptic dysfunction. Treatment with 1581 
G-quadruplex (G4) ligand 5-ALA represses Xlr3b transcription, antagonizing both 1582 
synaptic dysfunction and cognitive deficits in Atrx mutant mice.  1583 
 1584 
Supplementary Fig. 13. Full-size scans of western blots shown in figures. 1585 
 1586 
Supplementary Table 1. List of genes exhibiting differential expression in 1587 
hippocampus of P90 WT and AtrxΔE2 mice.  1588 
 1589 
Supplementary Table 2. Xlr3 interaction partners identified in proteomic screen 1590 




Supplementary Table 3. List of genes exhibiting differential expression in P90 WT, 1593 
AtrxΔE2 and 5-ALA treated AtrxΔE2 mouse hippocampus.  1594 
 1595 
Supplementary Table 4. List of genes exhibiting differential expression in P90 WT, 1596 
AtrxΔE2 and TMPyP4 treated AtrxΔE2 mouse hippocampus.  1597 
 1598 
Supplementary Table 5. Summary of all statistical data. 1599 
 1600 
Supplementary Video 1. Time-lapse imaging of GFP-MS2-labeled CaMKIIα 1601 
mRNA (GFP-CaMKIIα 3′ UTR) in a proximal dendrite of a cultured WT neuron.  1602 
 1603 
Supplementary Video 2. Time-lapse imaging of GFP-MS2-labeled CaMKIIα 1604 
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